ClinicalTrials.gg
Active, not recruitingNCT05405166IRAKLIAUpdated Sep 2, 2026Results posted

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

A Phase 3 interventional study of Isatuximab IV and Isatuximab SC in Plasma Cell Myeloma Recurrent, sponsored by Sanofi. Active, not recruiting at 128 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
531
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing isatuximab in Multiple Myeloma — 15 open to participants now, 34 under way, 9 of them phase 3. isatuximab · Multiple Myeloma.

Enrollment
4th of 50
531 · median 55
Started
2022
with 7 others
Phase 3
9 of 50
1 open now
Primary completion
2024-11
later than 1 of 33 live
Registered
33rd of 50
by date
Lead sponsor
13 of 50
Sanofi

Among the 50 studies testing isatuximab in Multiple Myeloma, this one is the 4th largest by enrollment, is one of 8 that started in 2022, is one of 9 in phase 3, reaches primary completion later than 1 of the 33 other live ones, and was the 33rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 50 studies testing isatuximab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About isatuximab

isatuximab: first FDA approval 2020 (SARCLISA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing isatuximab in Multiple Myeloma, or all of them as a file.
02

Study summary

This will be randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who will receive at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants were randomized 1:1 into 1 of 2 study arms:

Arm SC: Isatuximab SC + Pd

Arm IV: Isatuximab IV + Pd

Participants are allowed to continue therapy until disease progression, unacceptable adverse events (AEs), participant request to discontinue therapy or any other reason, whichever comes first.

Read the detailed description

Two study arms are treated in 4-week cycles until disease progression, unacceptable adverse events (AEs), participant request to discontinue therapy or any other reason, whichever comes first.

03

Conditions studied

  • Plasma Cell Myeloma Recurrent

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with multiple myeloma who have received at least one prior line of anti-myeloma therapy, which must include lenalidomide and a proteasome inhibitor given alone or in combination.
  • Measurable serum M-protein (≥ 0.5 g/dL) and/or urine M-protein (≥ 200 mg/24 hours) and/or serum free light chain (FLC) assay (Involved FLC assay ≥10 mg/dL and abnormal serum FLC ratio (\<0.26 or >1.65)).

Exclusion criteria

Exclusion Criteria:

  • Primary multiple myeloma participants
  • Participants with prior anti-CD38 treatment: (a) administered less than 9 months before randomization or, (b) intolerant to the anti-CD38 previously received
  • Prior therapy with pomalidomide
  • Participants with inadequate biological tests.
  • Significant cardiac dysfunction
  • Participants diagnosed or treated for another within 3 years prior to randomization with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, and in situ malignancy, or low risk prostate cancer after curative therapy
  • Concomitant plasma cell leukemia
  • Active primary amyloid light -chain amyloidosis
  • Known acquired immunodeficiency syndrome (AIDS)-related illness or known (HIV) disease requiring antiviral treatment
  • Know active Hepatitis A infection. Current active or chronic (HBV) or (HCV) infection. Participants with chronic HBV or HCV disease that is controlled under antiviral therapy are allowed.
  • Women of or male participant with women of childbearing potential who do not agree to use highly effective method of

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
531 participants (actual)

Study arms

  • Experimental
    Isatuximab Subcutaneous (SC)

    Isatuximab dose will administered SC weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and Day 1 and 15 of subsequent cycles. Each cycle will be 28 days in duration. Pomalidomide dose will be taken orally on Day 1 to Day 21 of each cycle at the time that is the most convenient for the participants prior to or after isatuximab administration, preferably at the same time every day. Dexamethasone will be taken orally on Day 1, 8, 15 and 22 (to be repeated every 28 days). Participants may receive other treatments as background treatment and/or rescue medication.

    Drug: Isatuximab SC · Drug: Dexamethasone · Drug: Pomalidomide · Drug: Montelukast · Drug: Paracetamol / Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone

  • Active comparator
    Isatuximab Intravenous (IV)

    Isatuximab dose will be administered via IV infusion weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and Day 1 and 15 of subsequent cycles. Each cycle will be 28 days. Pomalidomide dose will be taken orally on Day 1 to Day 21 of each cycle at the time that is the most convenient for the participants prior to or after isatuximab administration, preferably at the same time every day. Dexamethasone will be taken orally on Day 1, 8, 15 and 22 (to be repeated every 28 days). Participants may receive other treatments as background treatment and/or rescue medication.

    Drug: Isatuximab IV · Drug: Dexamethasone · Drug: Pomalidomide · Drug: Montelukast · Drug: Paracetamol / Acetaminophen · Drug: Diphenhydramine · Drug: Methylprednisolone

Interventions

  • Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous

    Also known as: SAR650984, SARCLISA®

  • Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)

    Also known as: SAR650984

  • Pharmaceutical form: Tablet; Route of administration: Oral

  • Pharmaceutical form: hard capsules; Route of administration: Oral

    Also known as: Pomalyst or equivalent

  • Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02

  • Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03

  • DrugParacetamol / Acetaminophen

    Drug page: Acetaminophen

    Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01

  • Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02

  • Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR by independent review committee (IRC) using 2016 international myeloma working group (IMWG) criteria:Percentage of participants with complete response (CR),stringent CR (sCR),very good partial response (VGPR) \& partial response (PR).CR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas (STP),\<5% plasma cells in bone marrow (BM) aspirates \& a normal free light chain(FLC)ratio (0.26-1.65).sCR:CR plus no clonal cells in BM biopsy. VGPR:serum \& urine M-protein detectable by immunofixation, not electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level\<100mg/24hour(h);\>=90% decrease in sum of maximal perpendicular diameter (SPD) compared to baseline in STP;FLC only:\>=90% decrease in difference between involved and uninvolved FLC levels.PR:\>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or to \<200mg/24h.In addition to above, if present at baseline,\>=50% reduction in size SPD of STPs also required.

    Time frame: From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months

  2. Observed Concentration Before Dosing (Ctrough) of Isatuximab at Steady State

    Ctrough at steady state was the observed plasma concentration collected on pre-dose at Cycle 6 Day 1 (equivalent to prior to Cycle 6 Day 1) of isatuximab administration dose.

    Time frame: Pre-dose at Cycle 6 Day 1

Secondary outcomes

  1. Very Good Partial Response or Better Rate

    VGPR or better rate by IRC using 2016 IMWG criteria: Percentage of participants with sCR, CR, and VGPR. CR: negative immunofixation on serum and urine, disappearance of any STP, \<5% plasma cells in BM aspirates \& normal FLC ratio (0.26-1.65). sCR: CR plus no clonal cells in BM biopsy. VGPR: serum and urine M-protein detectable by immunofixation, not electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level\<100mg/24h;\>=90% decrease in SPD compared to baseline in STP; FLC only:\>=90% decrease in difference between involved and uninvolved FLC levels. Percentages are rounded off to the tenth decimal place.

    Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months

  2. Ctrough of Isatuximab at 4 Weeks (CT4W)

    The CT4W was the observed plasma concentrations collected on pre-dose at Cycle 2 Day 1 (equivalent to prior to Cycle 2 Day 1) of isatuximab administration dose.

    Time frame: Pre-dose at Cycle 2 Day 1 (at 4 weeks)

  3. Percentage of Participants With Infusion Reactions

    Infusion reactions were graded using National Cancer Institute-Common Terminology Criteria for AE (NCI-CTCAE) version (v)5.0 criteria: Grade 1: mild transient reaction; infusion interruption not indicated; intervention not indicated. Grade 2: moderate reaction; therapy or infusion interruption indicated but responds promptly to symptomatic treatment; prophylactic medications indicated for \<=24 hours. Grade 3/4: severe or life-threatening reaction (Grade 3: prolonged \[not rapidly responsive to symptomatic medication and/or brief interruption of infusion\]; recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae. Grade 4: life-threatening consequences; urgent intervention indicated). Percentage of participants who observed AE of infusion reactions were collected through the electronic case report form (eCRF) as assessed by investigators. Percentages are rounded off to the tenth decimal place.

    Time frame: From first dose of study medication (Day 1) up to 30 days after the last dose of study medication, approximately 38 months

  4. Percentage of Participants Who Responded Very Satisfied and Satisfied to the 'Patient Experience and Satisfaction Questionnaire (PESQ-FU)': Satisfaction With Injection Method' (Item-8) at Cycle 5 Day 15

    The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'satisfaction with injection method' were recorded as 'very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied' at specified timepoints. The total percentage of participants who were very satisfied and satisfied with the injection method (item-8) at Cycle 5 Day 15 is reported here. Percentages are rounded off to the tenth decimal place.

    Time frame: Cycle 5 Day 15

  5. Duration of Response (DOR)

    DOR: Time from the date of first response to the date of first occurrence of progressive disease (PD) determined by IRC or death from any cause, whichever occurred first.DOR was determined only for participants who achieved a response (PR or better).If PD/death not observed, participant was censored at date of last valid disease assessment performed prior to initiating further anti-myeloma treatment or analysis cut-off date, whichever occurred first. As per IMWG criteria: PD: increase of \>=25% from lowest confirmed value in any 1 of following: serum M-protein (absolute increase\>=0.5 gram/deciliter\[g/dL\]),serum M-protein increase\>=1g/dL if lowest M-component \>=5g/dL, urine M-component (absolute increase \>=200mg/24h), appearance of new lesion(s),\>=50% increase from nadir in SPD of \>1 lesion or \>=50% increase in longest diameter of a previous lesion \>1 centimeter (cm) in short axis. PR: as defined in OM1.

    Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months

  6. Time to First Response (TT1R)

    TT1R was defined as the time from randomization to the date of first IRC determined response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or to \<200mg/24h. In addition to above, if present at baseline, \>=50% reduction in the size SPD of STPs was also required.

    Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months

  7. Time to Best Response (TTBR)

    TTBR was defined as the time from randomization to the date of first occurrence of IRC determined best overall response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or to \<200mg/24h. In addition to above, if present at baseline,\>=50% reduction in the size SPD of STPs was also required.

    Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months

  8. Progression-free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of first documentation of PD as determined by IRC or the date of death from any cause, whichever came first. Responses were determined according to IMWG criteria. PFS was censored at the date of the last valid disease assessment not showing PD performed prior to initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever came first.

    Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months

  9. Overall Survival (OS)

    OS was defined as the time from the date of randomization to death from any cause. Participants without death prior to the analysis cut-off date were censored at the last date the participant was known to be alive or the cut-off date, whichever was first.

    Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months

  10. Progression Free Survival 2 (PFS2)

    PFS2 was defined as time from the date of randomization to the date of first documentation of PD (as assessed by Investigator) after initiation of further anti-myeloma treatment or death from any cause, whichever happened first. Same censoring rule applies as in the PFS endpoint.

    Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months

  11. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An AE was defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.

    Time frame: From first dose of study medication (Day 1) up to 30 days after the last dose of study medication, approximately 38 months

  12. Isa-SC + Pd: Number of Participants With Injection Site Reactions (ISRs)

    The ISRs are defined as AEs related to medication administration with onset typically within 24 hours from the start of the infusion and are graded using NCI-CTCAE v5.0 criteria: Grade 1: tenderness with or without associated symptoms (warmth, erythema, itching). Grade 2: pain; lipodystrophy; edema; phlebitis. Grade 3: ulceration or necrosis severe tissue damage operative intervention indicated. Grade 4: life-threatening consequences; urgent intervention indicated. ISRs were collected through the eCRF. Number of participants with at least 1 ISR is reported. ISRs were applicable only for the SC administration.

    Time frame: From first dose of study medication (Day 1) up to 30 days after the last dose of study medication, approximately 38 months

  13. Ctrough of Isatuximab

    Plasma samples were collected at specified timepoints for the assessment of Ctrough.

    Time frame: Pre-dose on Cycle 1 Days 8, 15 and 22, Cycles 2 to 5 Days 1 and 15, Cycles 6, 7, 8, 9, 12, 15, 18, 21, 24 and 27 Day 1

  14. Isa-SC + Pd: Percentage of Successful Injections With Isatuximab Injector Device

    Percentage of successful injections with investigational isatuximab injector device was defined as completion of administration per provided instructions for use with no use errors or technical issues divided by the total number of injections x 100. Delivery performance of the device was analyzed based on the successful injection rate in the Isa-SC + Pd arm as the investigational isatuximab injector device was used only for SC administration.

    Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months

  15. Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Against Isatuximab

    A participant with treatment-emergent ADA was a participant with at least 1 treatment induced or treatment boosted ADA at any time during the treatment or follow-up observation period. Treatment-induced ADA was defined as ADAs developed de novo (seroconversion) following administration of the biotherapeutic (ie, formation of ADAs any time after the initial study medication administration in a participant without pre-existing ADAs). Treatment-boosted ADA was defined as pre-existing ADAs that were boosted to a higher level following administration of biotherapeutic (ie, any time after the initial study medication administration) the ADA titer was significantly higher than the baseline titer. Number of participants with treatment-emergent ADAs is presented.

    Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months

  16. Percentage of Participants With Response to 'Patient Expectation Questionnaire at Baseline (PEQ-BL)'

    Percentage of participants who responded that they strongly agree or agree at baseline with expectations of pain, discomfort and side effects from the injection method, the injection method would save time, study medication may result in side effects and would be worth taking are reported. PEQ-BL consisted of 7 items. Percentage of participants who ever received medication through IV and/or SC administration are also reported. Percentages are rounded off to the tenth decimal place. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1)

  17. Percentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Discomfort With Injection Method'

    The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'discomfort with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any discomfort with the injection method are reported here. Percentages are rounded off to the tenth decimal place.

    Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15

  18. Percentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Pain With Injection Method'

    The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'pain with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any pain with the injection method are reported here. Percentages are rounded off to the tenth decimal place.

    Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15

  19. Percentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Side Effects With Injection Method'

    The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'side effects with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any side effects with the injection method are reported here. Percentages are rounded off to the tenth decimal place.

    Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15

  20. Percentage of Participants Who Strongly Agreed and Agreed to 'PESQ-FU: Time Saving With Injection Method'

    The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'time saving with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who strongly agreed and agreed that they experienced time saving with the injection method are reported here. Percentages are rounded off to the tenth decimal place.

    Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15

  21. Percentage of Participants Who Responded Very Satisfied and Satisfied to 'PESQ-FU: Satisfaction With Injection Method'

    The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'satisfaction with injection method' were recorded as 'very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied' at specified timepoints. Percentage of participants who were very satisfied and satisfied with the injection method are reported here. Percentages are rounded off to the tenth decimal place.

    Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15

  22. Percentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Side Effects With Study Medication'

    The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'side effects with study medication' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any side effects with study medication are reported here. Percentages are rounded off to the tenth decimal place.

    Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15

  23. Percentage of Participants Who Strongly Agreed and Agreed to 'PESQ-FU: Study Medication Worth Taking'

    The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'study medication worth taking' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who strongly agreed and agreed that the study medication was worth taking are reported here. Percentages are rounded off to the tenth decimal place.

    Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15

  24. Percentage of Participants Who Responded Very Satisfied and Satisfied to 'PESQ-FU: Satisfaction With Study Medication'

    The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to satisfaction with study medication were recorded as 'very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied' at specified timepoints. Percentage of participants who were very satisfied and satisfied with the study medication are reported here. Percentages are rounded off to the tenth decimal place.

    Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15

  25. Percentage of Participants Who Responded Definitely Yes and Probably Yes to 'PESQ-FU: Recommendation of Study Medication'

    The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'recommendation of the study medication' were recorded as 'definitely yes, probably yes, unsure, probably not and definitely not' at specified timepoints. Percentage of participants who responded definitely yes and probably yes to the recommendation of study medication are reported here. Percentages are rounded off to the tenth decimal place.

    Time frame: Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15

  26. Percentage of Participants With Response to 'Patient Experience and Satisfaction End of Treatment Questionnaire (PESQ-EOT)'

    The PESQ-EOT consisting of 17 items assessed participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation) and has been adapted based on qualitative interviews with oncology participants. In addition to the above, this questionnaire also includes additional items to assess whether participants received oncology medications in the past 2 years and if a participant received both IV and SC in the past 2 years, then participant preference on injection method (whether SC or IV). Percentage of participants with response to these additional items (received oncology medications in the past 2 years via IV/SC/both and if received both IV and SC; then the participant preference on injection method) are reported here. Percentages are rounded off to the tenth decimal place.

    Time frame: EOT visit (up to DCO date: 29-Aug-2025) (30 days after last study medication administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 38 months)

  27. Participant Responses to Patient's Assessment of Treatment (PAT) Questionnaire

    The 4-item PAT is an internally developed non-disease specific and self-administered assessment which has been debriefed with oncology patients during qualitative interviews. It provided participant insights on the benefits and disadvantages of treatment. Benefits and disadvantages were respectively rated on a 0-10 scale wherein 0=none (not beneficial at all or no disadvantages at all) and 10=maximum (extremely beneficial or extremely disadvantageous). Disadvantages vs benefits were rated on a scale of -3 to 3 wherein -3=disadvantages significantly outweigh the benefits, 0=equal benefits and disadvantages and 3=benefits significantly outweigh the disadvantages. Mean of benefits, disadvantages and disadvantages vs benefits is presented here.

    Time frame: EOT visit (up to DCO date: 29-Aug-2025) (30 days after last study medication administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 38 months)

  28. Health Resource Utilization and Productivity Questionnaire (HRUPQ): Baseline Healthcare Utilization: Number of Times in the Past 6 Months a Participant Received Care

    Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of times in the past 6 months a participant received care in a clinic or hospital emergency room for any health issue including MM or due to MM and at-home care from a nurse or other health professional for any health issue including MM or due to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1)

  29. HRUPQ: Baseline Healthcare Utilization: Number of Nights in the Past 6 Months a Participant Stayed in Hospital

    Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of nights in the past 6 month a participant stayed in hospital for any health issue including MM or due to MM and stayed in intensive care unit (ICU) for any health issue including MM or due to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1)

  30. HRUPQ: Baseline Healthcare Utilization: Number of Times in the Past 6 Months a Participant Consulted a Healthcare Professional (HCP)

    Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of times in the past 6 months a participant consulted (had seen or talked to) following healthcare professionals: general doctor or primary care clinician (PCC) who treats a variety of illnesses for any health issue including MM or related to MM, physical or occupational therapist for any health issue including MM or related to MM, mental health professional (e.g. psychiatrist, psychologist, psychiatric nurse) for any health issue including MM or related to MM, medical doctor or clinician who specializes in particular medical disease or issue (specialist) for any health issue including MM or related to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1)

  31. Duration of Hospital Visits for Treatment Administration and Duration of Post-Treatment Monitoring Based on HRUPQ

    Medical resource utilization was collected through HRUPQ. Participants were asked to indicate the duration of their hospital visit (from arrival to departure) and the duration of post-treatment monitoring based on their most recent isatuximab administration. The median duration across all visits (starting from Cycle 2) was calculated and reported here.

    Time frame: From Cycle 2 Day 1 up to EOT visit (up to PCD: 06-Nov-2024) (30 days after last study medication administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 28 months)

  32. Percentage of Participants Who Visited Healthcare Professional for Non-trial-related Health Issues Based on HRUPQ

    Medical resource utilization was collected through HRUPQ. Percentage of participants with healthcare professional visit not required by clinical trial since last isatuximab administration was recorded. Percentages are rounded off to the tenth decimal place.

    Time frame: Cycle 1 Days 8, 15 and 22, Cycle 2 Day 1, Cycles 3 to 29 Day 15 and EOT visit (up to PCD: 06-Nov-2024) (30 days after last drug administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 28 months)

  33. Percentage of Participants Who Ever Retired During the Study Based on HRUPQ

    Employment status was assessed via HRUPQ. Percentage of participants who ever retired during the study are reported. Percentages are rounded off to the tenth decimal place.

    Time frame: From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months

  34. Percentage of Participants Who Retired Early Due to MM Based on HRUPQ

    Employment status was assessed via HRUPQ. Percentage of participants who retired early due to MM are reported. Percentages are rounded off to the tenth decimal place.

    Time frame: From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months

  35. Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QoL)

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For GHS/QoL: overall health and quality of life were assessed, rated on a 7-point scale (1: very poor to 7: excellent). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for GHS/QoL and a positive change from baseline represents a healthy/better level of QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  36. Change From Baseline in EORTC QLQ-C30: Physical Functioning

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of physical functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  37. Change From Baseline in EORTC QLQ-C30: Role Functioning

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of role functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  38. Change From Baseline in EORTC QLQ-C30: Emotional Functioning

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of emotional functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  39. Change From Baseline in EORTC QLQ-C30: Cognitive Functioning

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of cognitive functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  40. Change From Baseline in EORTC QLQ-C30: Social Functioning

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of social functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  41. Change From Baseline in EORTC QLQ-C30: Fatigue

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  42. Change From Baseline in EORTC QLQ-C30: Nausea and Vomiting

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  43. Change From Baseline in EORTC QLQ-C30: Pain

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  44. Change From Baseline in EORTC QLQ-C30: Dyspnea

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  45. Change From Baseline in EORTC QLQ-C30: Insomnia

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  46. Change From Baseline in EORTC QLQ-C30: Appetite Loss

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  47. Change From Baseline in EORTC QLQ-C30: Constipation

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  48. Change From Baseline in EORTC QLQ-C30: Diarrhea

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  49. Change From Baseline in EORTC QLQ-C30: Financial Difficulties

    EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of financial difficulties. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  50. Change From Baseline in EORTC QLQ-Myeloma Module (MY20): Disease Symptoms

    The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for disease symptoms and a positive change from baseline represents more symptoms, worse QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  51. Change From Baseline in EORTC QLQ-MY20: Side Effects of Treatment

    The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for side effects of treatment and a positive change from baseline represents more side effects, worse QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  52. Change From Baseline in EORTC QLQ-MY20: Future Perspective

    The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for future perspectives and a positive change from baseline represents better outcomes, better QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  53. Change From Baseline in EORTC QLQ-MY20: Body Image

    The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for body image and a positive change from baseline represents better outcomes, better QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)

  54. Change From Baseline in European Quality of Life Group Measure With 5 Dimensions and 5 Levels Per Dimension (EQ-5D-5L): Visual Analogue Scale (VAS)

    The EQ-5D-5L is a standardized measure of health status that provides a simple, generic measure of health utility, and consists of 2 sections: descriptive and a VAS. The descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The VAS records the respondent's self-rated health on a 20-cm vertical scale ranging from 0: the worst health you can imagine to 100: the best health you can imagine. Change from baseline in VAS is reported here. A higher score in VAS and positive change from baseline represents a better level of QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

    Time frame: Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 21 Day 15 and EOT visit (up to PCD: 06-Nov-2024) (30 days after last drug administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 28 months)

  55. ORR Based on at Least 1 Chromosomal Abnormality

    BM aspirate was collected for fluorescent in situ hybridization for analysis of del\[17p\], t\[4;14\], t\[14;16\]) and 1q21+. ORR was also evaluated based on IRC assessment by disease characteristics. ORR for participants with at least 1 chromosomal abnormality i.e. \[del(17p)\] or \[1q21+ and t(4;14) or t(14;16)\] is presented. Percentages are rounded off to the tenth decimal place.

    Time frame: From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months

07

Results

Posted Nov 14, 2025

Participant flow

This study was conducted at 120 sites in 21 countries. A total of 637 participants were screened from 23-Jun-2022 to 13-May-2024, of which 106 were screen failures. Screen failures were mainly due to not meeting eligibility criteria.

Participant flow — Overall Study
MilestoneIsa-IV + PdIsa-SC + Pd
Started268263
Randomized and treated264263
Completed00
Not completed268263
Withdrew: Death7377
Withdrew: Withdrawal by subject134
Withdrew: Ongoing at the time of dco182182

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR by independent review committee (IRC) using 2016 international myeloma working group (IMWG) criteria:Percentage of participants with complete response (CR),stringent CR (sCR),very good partial response (VGPR) \& partial response (PR).CR:negative immunofixation on serum and urine,disappearance of any soft tissue plasmacytomas (STP),\<5% plasma cells in bone marrow (BM) aspirates \& a normal free light chain(FLC)ratio (0.26-1.65).sCR:CR plus no clonal cells in BM biopsy. VGPR:serum \& urine M-protein detectable by immunofixation, not electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level\<100mg/24hour(h);\>=90% decrease in sum of maximal perpendicular diameter (SPD) compared to baseline in STP;FLC only:\>=90% decrease in difference between involved and uninvolved FLC levels.PR:\>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or to \<200mg/24h.In addition to above, if present at baseline,\>=50% reduction in size SPD of STPs also required.

Time frame:
From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsIsa-IV + PdIsa-SC + Pd
Overall Response Rate (ORR)70.571.1
Statistical analysis
  • Isa-IV + Pd vs Isa-SC + Pd · Farrington-Manning · p = 0.0006 · Relative risk: 1.008 · 95% CI 0.903 to 1.126Two-sided 95% CI estimated using Farrington-Manning method.
PrimaryObserved Concentration Before Dosing (Ctrough) of Isatuximab at Steady State

Ctrough at steady state was the observed plasma concentration collected on pre-dose at Cycle 6 Day 1 (equivalent to prior to Cycle 6 Day 1) of isatuximab administration dose.

Time frame:
Pre-dose at Cycle 6 Day 1
Reported as:
Mean · microgram/milliliter (mcg/mL)
Observed Concentration Before Dosing (Ctrough) of Isatuximab at Steady State
microgram/milliliter (mcg/mL)Isa-IV + PdIsa-SC + Pd
Observed Concentration Before Dosing (Ctrough) of Isatuximab at Steady State340 ± 169499 ± 259
Statistical analysis
  • Isa-IV + Pd vs Isa-SC + Pd · Ratio of geometric mean: 1.532 · 90% CI 1.316 to 1.784
SecondaryVery Good Partial Response or Better Rate

VGPR or better rate by IRC using 2016 IMWG criteria: Percentage of participants with sCR, CR, and VGPR. CR: negative immunofixation on serum and urine, disappearance of any STP, \<5% plasma cells in BM aspirates \& normal FLC ratio (0.26-1.65). sCR: CR plus no clonal cells in BM biopsy. VGPR: serum and urine M-protein detectable by immunofixation, not electrophoresis;\>=90% reduction in serum M-protein plus urine M-protein level\<100mg/24h;\>=90% decrease in SPD compared to baseline in STP; FLC only:\>=90% decrease in difference between involved and uninvolved FLC levels. Percentages are rounded off to the tenth decimal place.

Time frame:
From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Reported as:
Number · percentage of participants
Very Good Partial Response or Better Rate
percentage of participantsIsa-IV + PdIsa-SC + Pd
Very Good Partial Response or Better Rate53.050.2
Statistical analysis
  • Isa-IV + Pd vs Isa-SC + Pd · Farrington-Manning · p = <0.0001 · Relative risk: 0.947 · 95% CI 0.802 to 1.117Two-sided 95% CI estimated using Farrington-Manning method.
SecondaryCtrough of Isatuximab at 4 Weeks (CT4W)

The CT4W was the observed plasma concentrations collected on pre-dose at Cycle 2 Day 1 (equivalent to prior to Cycle 2 Day 1) of isatuximab administration dose.

Time frame:
Pre-dose at Cycle 2 Day 1 (at 4 weeks)
Reported as:
Mean · mcg/mL
Ctrough of Isatuximab at 4 Weeks (CT4W)
mcg/mLIsa-IV + PdIsa-SC + Pd
Ctrough of Isatuximab at 4 Weeks (CT4W)302 ± 117421 ± 215
Statistical analysis
  • Isa-IV + Pd vs Isa-SC + Pd · Ratio of geometric mean: 1.302 · 90% CI 1.158 to 1.465
SecondaryPercentage of Participants With Infusion Reactions

Infusion reactions were graded using National Cancer Institute-Common Terminology Criteria for AE (NCI-CTCAE) version (v)5.0 criteria: Grade 1: mild transient reaction; infusion interruption not indicated; intervention not indicated. Grade 2: moderate reaction; therapy or infusion interruption indicated but responds promptly to symptomatic treatment; prophylactic medications indicated for \<=24 hours. Grade 3/4: severe or life-threatening reaction (Grade 3: prolonged \[not rapidly responsive to symptomatic medication and/or brief interruption of infusion\]; recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae. Grade 4: life-threatening consequences; urgent intervention indicated). Percentage of participants who observed AE of infusion reactions were collected through the electronic case report form (eCRF) as assessed by investigators. Percentages are rounded off to the tenth decimal place.

Time frame:
From first dose of study medication (Day 1) up to 30 days after the last dose of study medication, approximately 38 months
Reported as:
Number · percentage of participants
Percentage of Participants With Infusion Reactions
percentage of participantsIsa-IV + PdIsa-SC + Pd
Percentage of Participants With Infusion Reactions25.0 (19.89 to 30.68)1.9 (0.62 to 4.38)
Statistical analysis
  • Isa-IV + Pd vs Isa-SC + Pd · Fisher Exact · p = <0.0001 · Relative risk: 0.076 · 95% CI 0.031 to 0.186Two-sided 95% CI estimated using Wald method.
SecondaryPercentage of Participants Who Responded Very Satisfied and Satisfied to the 'Patient Experience and Satisfaction Questionnaire (PESQ-FU)': Satisfaction With Injection Method' (Item-8) at Cycle 5 Day 15

The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'satisfaction with injection method' were recorded as 'very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied' at specified timepoints. The total percentage of participants who were very satisfied and satisfied with the injection method (item-8) at Cycle 5 Day 15 is reported here. Percentages are rounded off to the tenth decimal place.

Time frame:
Cycle 5 Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Responded Very Satisfied and Satisfied to the 'Patient Experience and Satisfaction Questionnaire (PESQ-FU)': Satisfaction With Injection Method' (Item-8) at Cycle 5 Day 15
percentage of participantsIsa-IV + PdIsa-SC + Pd
Percentage of Participants Who Responded Very Satisfied and Satisfied to the 'Patient Experience and Satisfaction Questionnaire (PESQ-FU)': Satisfaction With Injection Method' (Item-8) at Cycle 5 Day 1554.171.1
Statistical analysis
  • Isa-IV + Pd vs Isa-SC + Pd · Cochran-Mantel-Haenszel · p = 0.0001 (Stratified on multiple myeloma (MM) isotype (immunoglobulin G \[IgG\] versus non-IgG), body weight (\<=65 kg, \>65 to \<=85 kg, and \>85 kg), and number of prior lines (1 to 2 versus \>=3) according to IRT.) · Odds ratio (or): 2.087 · 95% CI 1.458 to 2.988Two-sided 95% CI estimated using the Wald method.
SecondaryDuration of Response (DOR)

DOR: Time from the date of first response to the date of first occurrence of progressive disease (PD) determined by IRC or death from any cause, whichever occurred first.DOR was determined only for participants who achieved a response (PR or better).If PD/death not observed, participant was censored at date of last valid disease assessment performed prior to initiating further anti-myeloma treatment or analysis cut-off date, whichever occurred first. As per IMWG criteria: PD: increase of \>=25% from lowest confirmed value in any 1 of following: serum M-protein (absolute increase\>=0.5 gram/deciliter\[g/dL\]),serum M-protein increase\>=1g/dL if lowest M-component \>=5g/dL, urine M-component (absolute increase \>=200mg/24h), appearance of new lesion(s),\>=50% increase from nadir in SPD of \>1 lesion or \>=50% increase in longest diameter of a previous lesion \>1 centimeter (cm) in short axis. PR: as defined in OM1.

Time frame:
From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Reported as:
Median · months
Duration of Response (DOR)
monthsIsa-IV + PdIsa-SC + Pd
Duration of Response (DOR)29.04 (25.791 to NA)NA (22.177 to NA)
SecondaryTime to First Response (TT1R)

TT1R was defined as the time from randomization to the date of first IRC determined response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or to \<200mg/24h. In addition to above, if present at baseline, \>=50% reduction in the size SPD of STPs was also required.

Time frame:
From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Reported as:
Median · months
Time to First Response (TT1R)
monthsIsa-IV + PdIsa-SC + Pd
Time to First Response (TT1R)1.87 (1.183 to 1.938)2.04 (1.906 to 2.793)
SecondaryTime to Best Response (TTBR)

TTBR was defined as the time from randomization to the date of first occurrence of IRC determined best overall response (PR or better) that was subsequently confirmed. PR as per IMWG criteria was defined as \>=50% reduction of serum M-protein and reduction in 24h urine M-protein by \>=90% or to \<200mg/24h. In addition to above, if present at baseline,\>=50% reduction in the size SPD of STPs was also required.

Time frame:
From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Reported as:
Median · months
Time to Best Response (TTBR)
monthsIsa-IV + PdIsa-SC + Pd
Time to Best Response (TTBR)5.59 (4.698 to 6.439)5.78 (5.322 to 6.669)
SecondaryProgression-free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of first documentation of PD as determined by IRC or the date of death from any cause, whichever came first. Responses were determined according to IMWG criteria. PFS was censored at the date of the last valid disease assessment not showing PD performed prior to initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever came first.

Time frame:
From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsIsa-IV + PdIsa-SC + Pd
Progression-free Survival (PFS)26.91 (15.934 to NA)20.34 (16.986 to 25.561)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization to death from any cause. Participants without death prior to the analysis cut-off date were censored at the last date the participant was known to be alive or the cut-off date, whichever was first.

Time frame:
From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Reported as:
Median · months
Overall Survival (OS)
monthsIsa-IV + PdIsa-SC + Pd
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryProgression Free Survival 2 (PFS2)

PFS2 was defined as time from the date of randomization to the date of first documentation of PD (as assessed by Investigator) after initiation of further anti-myeloma treatment or death from any cause, whichever happened first. Same censoring rule applies as in the PFS endpoint.

Time frame:
From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Reported as:
Median · months
Progression Free Survival 2 (PFS2)
monthsIsa-IV + PdIsa-SC + Pd
Progression Free Survival 2 (PFS2)NA (24.608 to NA)NA (24.082 to NA)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An AE was defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. SAEs were any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.

Time frame:
From first dose of study medication (Day 1) up to 30 days after the last dose of study medication, approximately 38 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsIsa-IV + PdIsa-SC + Pd
TEAEs263258
TESAEs152160
SecondaryIsa-SC + Pd: Number of Participants With Injection Site Reactions (ISRs)

The ISRs are defined as AEs related to medication administration with onset typically within 24 hours from the start of the infusion and are graded using NCI-CTCAE v5.0 criteria: Grade 1: tenderness with or without associated symptoms (warmth, erythema, itching). Grade 2: pain; lipodystrophy; edema; phlebitis. Grade 3: ulceration or necrosis severe tissue damage operative intervention indicated. Grade 4: life-threatening consequences; urgent intervention indicated. ISRs were collected through the eCRF. Number of participants with at least 1 ISR is reported. ISRs were applicable only for the SC administration.

Time frame:
From first dose of study medication (Day 1) up to 30 days after the last dose of study medication, approximately 38 months
Reported as:
Count of participants · Participants
Isa-SC + Pd: Number of Participants With Injection Site Reactions (ISRs)
ParticipantsIsa-SC + Pd
Isa-SC + Pd: Number of Participants With Injection Site Reactions (ISRs)12
SecondaryCtrough of Isatuximab

Plasma samples were collected at specified timepoints for the assessment of Ctrough.

Time frame:
Pre-dose on Cycle 1 Days 8, 15 and 22, Cycles 2 to 5 Days 1 and 15, Cycles 6, 7, 8, 9, 12, 15, 18, 21, 24 and 27 Day 1
Reported as:
Mean · mcg/mL
Ctrough of Isatuximab
mcg/mLIsa-IV + PdIsa-SC + Pd
Cycle 1 Day 892 ± 47129 ± 66
Cycle 1 Day 15171 ± 84249 ± 115
Cycle 1 Day 22227 ± 99321 ± 144
Cycle 2 Day 1293 ± 117407 ± 211
Cycle 2 Day 15243 ± 130363 ± 228
Cycle 3 Day 1268 ± 133381 ± 192
Cycle 3 Day 15256 ± 138392 ± 245
Cycle 4 Day 1277 ± 151477 ± 424
Cycle 4 Day 15285 ± 139452 ± 400
Cycle 5 Day 1366 ± 568470 ± 264
Cycle 5 Day 15306 ± 168463 ± 275
Cycle 6 Day 1330 ± 165491 ± 256
Cycle 7 Day 1339 ± 189523 ± 336
Cycle 8 Day 1348 ± 172569 ± 336
Cycle 9 Day 1365 ± 193598 ± 369
Cycle 12 Day 1380 ± 214593 ± 404
Cycle 15 Day 1354 ± 158651 ± 361
Cycle 18 Day 1367 ± 140645 ± 343
Cycle 21 Day 1388 ± 174668 ± 213
Cycle 24 Day 1525 ± 455651 ± 424
Cycle 27 Day 1—566 ± 200
SecondaryIsa-SC + Pd: Percentage of Successful Injections With Isatuximab Injector Device

Percentage of successful injections with investigational isatuximab injector device was defined as completion of administration per provided instructions for use with no use errors or technical issues divided by the total number of injections x 100. Delivery performance of the device was analyzed based on the successful injection rate in the Isa-SC + Pd arm as the investigational isatuximab injector device was used only for SC administration.

Time frame:
From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Reported as:
Number · percentage of successful injections
Isa-SC + Pd: Percentage of Successful Injections With Isatuximab Injector Device
percentage of successful injectionsIsa-SC + Pd
Isa-SC + Pd: Percentage of Successful Injections With Isatuximab Injector Device99.0
SecondaryNumber of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Against Isatuximab

A participant with treatment-emergent ADA was a participant with at least 1 treatment induced or treatment boosted ADA at any time during the treatment or follow-up observation period. Treatment-induced ADA was defined as ADAs developed de novo (seroconversion) following administration of the biotherapeutic (ie, formation of ADAs any time after the initial study medication administration in a participant without pre-existing ADAs). Treatment-boosted ADA was defined as pre-existing ADAs that were boosted to a higher level following administration of biotherapeutic (ie, any time after the initial study medication administration) the ADA titer was significantly higher than the baseline titer. Number of participants with treatment-emergent ADAs is presented.

Time frame:
From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Against Isatuximab
ParticipantsIsa-IV + PdIsa-SC + Pd
Number of Participants With Treatment-emergent Anti-drug Antibodies (ADA) Against Isatuximab2918
SecondaryPercentage of Participants With Response to 'Patient Expectation Questionnaire at Baseline (PEQ-BL)'

Percentage of participants who responded that they strongly agree or agree at baseline with expectations of pain, discomfort and side effects from the injection method, the injection method would save time, study medication may result in side effects and would be worth taking are reported. PEQ-BL consisted of 7 items. Percentage of participants who ever received medication through IV and/or SC administration are also reported. Percentages are rounded off to the tenth decimal place. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1)
Reported as:
Number · percentage of participants
Percentage of Participants With Response to 'Patient Expectation Questionnaire at Baseline (PEQ-BL)'
percentage of participantsIsa-IV + PdIsa-SC + Pd
Injection method may be painful: strongly agree6.07.9
Injection method may be painful: agree33.633.3
Injection method may be uncomfortable: strongly agree11.19.6
Injection method may be uncomfortable: agree37.825.9
Injection method may result in side effects: strongly agree9.24.8
Injection method may result in side effects: agree42.945.2
Injection method will save me time: strongly agree9.221.1
Injection method will save me time: agree31.851.8
Study medication may result in side effects: strongly agree12.97.9
Study medication may result in side effects: agree47.544.3
Study medication would be worth taking: strongly agree26.726.8
Study medication would be worth taking: agree47.047.8
Ever received medication through IV74.262.3
Ever received medication through SC48.861.4
Neither received medication ever via IV or SC9.26.1
SecondaryPercentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Discomfort With Injection Method'

The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'discomfort with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any discomfort with the injection method are reported here. Percentages are rounded off to the tenth decimal place.

Time frame:
Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Discomfort With Injection Method'
percentage of participantsIsa-IV + PdIsa-SC + Pd
Cycle 1 Day 8: disagree33.240.1
Cycle 1 Day 8: strongly disagree14.736.5
Cycle 1 Day 15: disagree39.043.2
Cycle 1 Day 15: strongly disagree15.238.3
Cycle 1 Day 22: disagree39.645.0
Cycle 1 Day 22: strongly disagree13.232.5
Cycle 2 Day 1: disagree41.248.9
Cycle 2 Day 1: strongly disagree13.331.7
Cycle 2 Day 15: disagree41.247.9
Cycle 2 Day 15: strongly disagree14.534.1
Cycle 3 Day 1: disagree38.544.9
Cycle 3 Day 1: strongly disagree13.833.3
Cycle 4 Day 1: disagree36.344.2
Cycle 4 Day 1: strongly disagree16.537.7
Cycle 5 Day 15: disagree38.746.6
Cycle 5 Day 15: strongly disagree15.232.1
Cycle 6 Day 15: disagree36.242.4
Cycle 6 Day 15: strongly disagree13.840.7
Cycle 7 Day 15: disagree33.542.7
Cycle 7 Day 15: strongly disagree16.840.9
Cycle 8 Day 15: disagree34.544.4
Cycle 8 Day 15: strongly disagree18.839.5
Cycle 9 Day 15: disagree33.541.7
Cycle 9 Day 15: strongly disagree20.337.5
Cycle 10 Day 15: disagree36.040.7
Cycle 10 Day 15: strongly disagree19.346.0
Cycle 11 Day 15: disagree32.039.0
Cycle 11 Day 15: strongly disagree19.344.7
Cycle 12 Day 15: disagree30.542.2
Cycle 12 Day 15: strongly disagree21.442.2
Cycle 13 Day 15: disagree33.646.3
Cycle 13 Day 15: strongly disagree17.642.3
Cycle 14 Day 15: disagree30.945.6
Cycle 14 Day 15: strongly disagree20.340.0
Cycle 15 Day 15: disagree28.936.5
Cycle 15 Day 15: strongly disagree20.241.7
Cycle 16 Day 15: disagree27.938.9
Cycle 16 Day 15: strongly disagree20.247.2
Cycle 17 Day 15: disagree29.841.1
Cycle 17 Day 15: strongly disagree18.145.3
Cycle 18 Day 15: disagree37.239.3
Cycle 18 Day 15: strongly disagree12.847.6
Cycle 19 Day 15: disagree37.036.6
Cycle 19 Day 15: strongly disagree16.445.1
Cycle 20 Day 15: disagree37.943.9
Cycle 20 Day 15: strongly disagree19.045.6
Cycle 21 Day 15: disagree38.240.4
Cycle 21 Day 15: strongly disagree7.346.8
Cycle 22 Day 15: disagree29.443.9
Cycle 22 Day 15: strongly disagree11.851.2
Cycle 23 Day 15: disagree32.536.1
Cycle 23 Day 15: strongly disagree7.552.8
Cycle 24 Day 15: disagree22.038.7
Cycle 24 Day 15: strongly disagree17.148.4
Cycle 25 Day 15: disagree20.046.2
Cycle 25 Day 15: strongly disagree17.150.0
Cycle 26 Day 15: disagree25.048.0
Cycle 26 Day 15: strongly disagree14.352.0
Cycle 27 Day 15: disagree21.740.0
Cycle 27 Day 15: strongly disagree17.446.7
Cycle 28 Day 15: disagree31.350.0
Cycle 28 Day 15: strongly disagree25.050.0
Cycle 29 Day 15: disagree25.053.8
Cycle 29 Day 15: strongly disagree25.046.2
Cycle 30 Day 15: disagree28.655.6
Cycle 30 Day 15: strongly disagree28.644.4
Cycle 31 Day 15: disagree55.650.0
Cycle 31 Day 15: strongly disagree11.150.0
Cycle 32 Day 15: disagree37.575.0
Cycle 32 Day 15: strongly disagree12.525.0
Cycle 33 Day 15: disagree50.050.0
Cycle 33 Day 15: strongly disagree16.750.0
Cycle 34 Day 15: disagree75.075.0
Cycle 34 Day 15: strongly disagree025.0
Cycle 35 Day 15: disagree75.0100
Cycle 35 Day 15: strongly disagree00
Cycle 36 Day 15: disagree100100
Cycle 36 Day 15: strongly disagree00
Cycle 37 Day 15: disagree100100
Cycle 37 Day 15: strongly disagree00
Cycle 38 Day 15: disagree100100
Cycle 38 Day 15: strongly disagree00
Cycle 39 Day 15: disagree—100
Cycle 39 Day 15: strongly disagree—0
SecondaryPercentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Pain With Injection Method'

The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'pain with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any pain with the injection method are reported here. Percentages are rounded off to the tenth decimal place.

Time frame:
Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Pain With Injection Method'
percentage of participantsIsa-IV + PdIsa-SC + Pd
Cycle 1 Day 8: disagree44.742.8
Cycle 1 Day 8: strongly disagree19.840.5
Cycle 1 Day 15: disagree47.144.7
Cycle 1 Day 15: strongly disagree19.540.3
Cycle 1 Day 22: disagree43.445.9
Cycle 1 Day 22: strongly disagree19.836.8
Cycle 2 Day 1: disagree49.451.5
Cycle 2 Day 1: strongly disagree17.235.2
Cycle 2 Day 15: disagree47.550.2
Cycle 2 Day 15: strongly disagree17.237.4
Cycle 3 Day 1: disagree45.051.4
Cycle 3 Day 1: strongly disagree17.036.1
Cycle 4 Day 1: disagree43.446.5
Cycle 4 Day 1: strongly disagree18.439.5
Cycle 5 Day 15: disagree46.150.8
Cycle 5 Day 15: strongly disagree17.238.3
Cycle 6 Day 15: disagree44.848.3
Cycle 6 Day 15: strongly disagree17.842.4
Cycle 7 Day 15: disagree46.247.6
Cycle 7 Day 15: strongly disagree19.742.1
Cycle 8 Day 15: disagree38.846.3
Cycle 8 Day 15: strongly disagree23.040.7
Cycle 9 Day 15: disagree41.841.7
Cycle 9 Day 15: strongly disagree25.344.4
Cycle 10 Day 15: disagree42.042.7
Cycle 10 Day 15: strongly disagree24.049.3
Cycle 11 Day 15: disagree40.041.1
Cycle 11 Day 15: strongly disagree22.048.9
Cycle 12 Day 15: disagree43.543.7
Cycle 12 Day 15: strongly disagree22.144.4
Cycle 13 Day 15: disagree43.248.8
Cycle 13 Day 15: strongly disagree19.242.3
Cycle 14 Day 15: disagree38.242.4
Cycle 14 Day 15: strongly disagree22.844.8
Cycle 15 Day 15: disagree38.640.9
Cycle 15 Day 15: strongly disagree21.945.2
Cycle 16 Day 15: disagree35.641.7
Cycle 16 Day 15: strongly disagree23.148.1
Cycle 17 Day 15: disagree41.548.4
Cycle 17 Day 15: strongly disagree20.242.1
Cycle 18 Day 15: disagree47.741.7
Cycle 18 Day 15: strongly disagree20.951.2
Cycle 19 Day 15: disagree45.243.7
Cycle 19 Day 15: strongly disagree16.446.5
Cycle 20 Day 15: disagree44.845.6
Cycle 20 Day 15: strongly disagree17.247.4
Cycle 21 Day 15: disagree47.338.3
Cycle 21 Day 15: strongly disagree10.953.2
Cycle 22 Day 15: disagree45.146.3
Cycle 22 Day 15: strongly disagree13.753.7
Cycle 23 Day 15: disagree55.036.1
Cycle 23 Day 15: strongly disagree12.558.3
Cycle 24 Day 15: disagree34.125.8
Cycle 24 Day 15: strongly disagree19.551.6
Cycle 25 Day 15: disagree42.942.3
Cycle 25 Day 15: strongly disagree22.950.0
Cycle 26 Day 15: disagree32.148.0
Cycle 26 Day 15: strongly disagree14.352.0
Cycle 27 Day 15: disagree43.540.0
Cycle 27 Day 15: strongly disagree17.446.7
Cycle 28 Day 15: disagree37.542.9
Cycle 28 Day 15: strongly disagree18.850.0
Cycle 29 Day 15: disagree31.353.8
Cycle 29 Day 15: strongly disagree31.346.2
Cycle 30 Day 15: disagree28.655.6
Cycle 30 Day 15: strongly disagree28.644.4
Cycle 31 Day 15: disagree55.650.0
Cycle 31 Day 15: strongly disagree11.150.0
Cycle 32 Day 15: disagree37.575.0
Cycle 32 Day 15: strongly disagree25.025.0
Cycle 33 Day 15: disagree66.750.0
Cycle 33 Day 15: strongly disagree16.750.0
Cycle 34 Day 15: disagree75.075.0
Cycle 34 Day 15: strongly disagree025.0
Cycle 35 Day 15: disagree75.0100.0
Cycle 35 Day 15: strongly disagree00
Cycle 36 Day 15: disagree100100
Cycle 36 Day 15: strongly disagree00
Cycle 37 Day 15: disagree100100
Cycle 37 Day 15: strongly disagree00
Cycle 38 Day 15: disagree100100
Cycle 38 Day 15: strongly disagree00
Cycle 39 Day 15: disagree—100
Cycle 39 Day 15: strongly disagree—0
SecondaryPercentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Side Effects With Injection Method'

The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'side effects with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any side effects with the injection method are reported here. Percentages are rounded off to the tenth decimal place.

Time frame:
Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Side Effects With Injection Method'
percentage of participantsIsa-IV + PdIsa-SC + Pd
Cycle 1 Day 8: disagree41.046.4
Cycle 1 Day 8: strongly disagree18.027.9
Cycle 1 Day 15: disagree41.045.6
Cycle 1 Day 15: strongly disagree15.225.2
Cycle 1 Day 22: disagree44.342.1
Cycle 1 Day 22: strongly disagree12.723.4
Cycle 2 Day 1: disagree46.451.1
Cycle 2 Day 1: strongly disagree12.023.8
Cycle 2 Day 15: disagree44.849.3
Cycle 2 Day 15: strongly disagree12.225.6
Cycle 3 Day 1: disagree43.147.7
Cycle 3 Day 1: strongly disagree13.328.2
Cycle 4 Day 1: disagree42.953.5
Cycle 4 Day 1: strongly disagree11.826.0
Cycle 5 Day 15: disagree44.148.2
Cycle 5 Day 15: strongly disagree14.729.0
Cycle 6 Day 15: disagree45.446.5
Cycle 6 Day 15: strongly disagree13.232.6
Cycle 7 Day 15: disagree43.450.0
Cycle 7 Day 15: strongly disagree16.233.5
Cycle 8 Day 15: disagree35.846.9
Cycle 8 Day 15: strongly disagree21.832.7
Cycle 9 Day 15: disagree35.443.8
Cycle 9 Day 15: strongly disagree22.238.2
Cycle 10 Day 15: disagree45.338.7
Cycle 10 Day 15: strongly disagree19.344.0
Cycle 11 Day 15: disagree38.039.0
Cycle 11 Day 15: strongly disagree18.739.7
Cycle 12 Day 15: disagree42.748.9
Cycle 12 Day 15: strongly disagree16.834.1
Cycle 13 Day 15: disagree41.646.3
Cycle 13 Day 15: strongly disagree16.835.8
Cycle 14 Day 15: disagree35.049.6
Cycle 14 Day 15: strongly disagree17.934.4
Cycle 15 Day 15: disagree37.741.7
Cycle 15 Day 15: strongly disagree18.437.4
Cycle 16 Day 15: disagree32.738.9
Cycle 16 Day 15: strongly disagree20.238.9
Cycle 17 Day 15: disagree40.443.2
Cycle 17 Day 15: strongly disagree19.140.0
Cycle 18 Day 15: disagree41.942.9
Cycle 18 Day 15: strongly disagree15.140.5
Cycle 19 Day 15: disagree41.140.8
Cycle 19 Day 15: strongly disagree16.443.7
Cycle 20 Day 15: disagree34.545.6
Cycle 20 Day 15: strongly disagree24.140.4
Cycle 21 Day 15: disagree47.331.9
Cycle 21 Day 15: strongly disagree10.951.1
Cycle 22 Day 15: disagree41.248.8
Cycle 22 Day 15: strongly disagree19.641.5
Cycle 23 Day 15: disagree45.041.7
Cycle 23 Day 15: strongly disagree17.544.4
Cycle 24 Day 15: disagree36.641.9
Cycle 24 Day 15: strongly disagree22.038.7
Cycle 25 Day 15: disagree37.142.3
Cycle 25 Day 15: strongly disagree25.742.3
Cycle 26 Day 15: disagree35.740.0
Cycle 26 Day 15: strongly disagree32.148.0
Cycle 27 Day 15: disagree39.126.7
Cycle 27 Day 15: strongly disagree30.446.7
Cycle 28 Day 15: disagree43.857.1
Cycle 28 Day 15: strongly disagree31.335.7
Cycle 29 Day 15: disagree43.838.5
Cycle 29 Day 15: strongly disagree18.838.5
Cycle 30 Day 15: disagree35.744.4
Cycle 30 Day 15: strongly disagree42.944.4
Cycle 31 Day 15: disagree44.433.3
Cycle 31 Day 15: strongly disagree22.250.0
Cycle 32 Day 15: disagree50.050.0
Cycle 32 Day 15: strongly disagree12.525.0
Cycle 33 Day 15: disagree33.333.3
Cycle 33 Day 15: strongly disagree33.350.0
Cycle 34 Day 15: disagree25.050.0
Cycle 34 Day 15: strongly disagree25.025.0
Cycle 35 Day 15: disagree25.0100.0
Cycle 35 Day 15: strongly disagree25.00
Cycle 36 Day 15: disagree50.066.7
Cycle 36 Day 15: strongly disagree50.00
Cycle 37 Day 15: disagree100100
Cycle 37 Day 15: strongly disagree00
Cycle 38 Day 15: disagree0100
Cycle 38 Day 15: strongly disagree1000
Cycle 39 Day 15: disagree—0
Cycle 39 Day 15: strongly disagree—0
SecondaryPercentage of Participants Who Strongly Agreed and Agreed to 'PESQ-FU: Time Saving With Injection Method'

The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'time saving with injection method' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who strongly agreed and agreed that they experienced time saving with the injection method are reported here. Percentages are rounded off to the tenth decimal place.

Time frame:
Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Strongly Agreed and Agreed to 'PESQ-FU: Time Saving With Injection Method'
percentage of participantsIsa-IV + PdIsa-SC + Pd
Cycle 1 Day 8: strongly agree5.536.9
Cycle 1 Day 8: agree20.737.4
Cycle 1 Day 15: strongly agree3.342.2
Cycle 1 Day 15: agree25.738.3
Cycle 1 Day 22: strongly agree5.235.9
Cycle 1 Day 22: agree22.245.9
Cycle 2 Day 1: strongly agree5.634.8
Cycle 2 Day 1: agree25.846.3
Cycle 2 Day 15: strongly agree5.432.7
Cycle 2 Day 15: agree28.148.8
Cycle 3 Day 1: strongly agree3.738.4
Cycle 3 Day 1: agree25.745.8
Cycle 4 Day 1: strongly agree7.538.1
Cycle 4 Day 1: agree22.643.3
Cycle 5 Day 15: strongly agree9.339.4
Cycle 5 Day 15: agree23.043.5
Cycle 6 Day 15: strongly agree7.541.3
Cycle 6 Day 15: agree28.739.5
Cycle 7 Day 15: strongly agree6.941.5
Cycle 7 Day 15: agree28.940.9
Cycle 8 Day 15: strongly agree12.138.3
Cycle 8 Day 15: agree21.844.4
Cycle 9 Day 15: strongly agree8.945.1
Cycle 9 Day 15: agree26.639.6
Cycle 10 Day 15: strongly agree9.342.0
Cycle 10 Day 15: agree22.038.0
Cycle 11 Day 15: strongly agree7.346.1
Cycle 11 Day 15: agree28.039.0
Cycle 12 Day 15: strongly agree8.443.7
Cycle 12 Day 15: agree25.241.5
Cycle 13 Day 15: strongly agree8.843.1
Cycle 13 Day 15: agree28.042.3
Cycle 14 Day 15: strongly agree10.640.0
Cycle 14 Day 15: agree20.342.4
Cycle 15 Day 15: strongly agree11.447.0
Cycle 15 Day 15: agree21.946.1
Cycle 16 Day 15: strongly agree14.449.1
Cycle 16 Day 15: agree23.136.1
Cycle 17 Day 15: strongly agree11.752.6
Cycle 17 Day 15: agree22.337.9
Cycle 18 Day 15: strongly agree10.546.4
Cycle 18 Day 15: agree30.245.2
Cycle 19 Day 15: strongly agree12.346.5
Cycle 19 Day 15: agree23.343.7
Cycle 20 Day 15: strongly agree10.352.6
Cycle 20 Day 15: agree20.735.1
Cycle 21 Day 15: strongly agree3.661.7
Cycle 21 Day 15: agree23.631.9
Cycle 22 Day 15: strongly agree7.848.8
Cycle 22 Day 15: agree29.441.5
Cycle 23 Day 15: strongly agree7.544.4
Cycle 23 Day 15: agree27.547.2
Cycle 24 Day 15: strongly agree9.851.6
Cycle 24 Day 15: agree29.341.9
Cycle 25 Day 15: strongly agree20.046.2
Cycle 25 Day 15: agree22.934.6
Cycle 26 Day 15: strongly agree21.452.0
Cycle 26 Day 15: agree21.432.0
Cycle 27 Day 15: strongly agree17.453.3
Cycle 27 Day 15: agree26.140.0
Cycle 28 Day 15: strongly agree25.050.0
Cycle 28 Day 15: agree31.328.6
Cycle 29 Day 15: strongly agree25.046.2
Cycle 29 Day 15: agree31.338.5
Cycle 30 Day 15: strongly agree21.444.4
Cycle 30 Day 15: agree42.944.4
Cycle 31 Day 15: strongly agree22.250.0
Cycle 31 Day 15: agree55.633.3
Cycle 32 Day 15: strongly agree25.025.0
Cycle 32 Day 15: agree50.050.0
Cycle 33 Day 15: strongly agree16.733.3
Cycle 33 Day 15: agree66.733.3
Cycle 34 Day 15: strongly agree050.0
Cycle 34 Day 15: agree10025.0
Cycle 35 Day 15: strongly agree033.3
Cycle 35 Day 15: agree10033.3
Cycle 36 Day 15: strongly agree033.3
Cycle 36 Day 15: agree10033.3
Cycle 37 Day 15: strongly agree050.0
Cycle 37 Day 15: agree1000
Cycle 38 Day 15: strongly agree050.0
Cycle 38 Day 15: agree1000
Cycle 39 Day 15: strongly agree—0
Cycle 39 Day 15: agree—0
SecondaryPercentage of Participants Who Responded Very Satisfied and Satisfied to 'PESQ-FU: Satisfaction With Injection Method'

The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'satisfaction with injection method' were recorded as 'very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied' at specified timepoints. Percentage of participants who were very satisfied and satisfied with the injection method are reported here. Percentages are rounded off to the tenth decimal place.

Time frame:
Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Responded Very Satisfied and Satisfied to 'PESQ-FU: Satisfaction With Injection Method'
percentage of participantsIsa-IV + PdIsa-SC + Pd
Cycle 1 Day 8: very satisfied12.935.6
Cycle 1 Day 8: satisfied53.053.2
Cycle 1 Day 15: very satisfied16.743.2
Cycle 1 Day 15: satisfied51.447.1
Cycle 1 Day 22: very satisfied9.936.4
Cycle 1 Day 22: satisfied54.752.6
Cycle 2 Day 1: very satisfied12.439.2
Cycle 2 Day 1: satisfied52.448.9
Cycle 2 Day 15: very satisfied14.940.3
Cycle 2 Day 15: satisfied54.352.1
Cycle 3 Day 1: very satisfied13.841.7
Cycle 3 Day 1: satisfied57.348.1
Cycle 4 Day 1: very satisfied14.243.3
Cycle 4 Day 1: satisfied55.750.7
Cycle 5 Day 15: very satisfied18.649.2
Cycle 5 Day 15: satisfied52.047.7
Cycle 6 Day 15: very satisfied15.545.9
Cycle 6 Day 15: satisfied53.445.9
Cycle 7 Day 15: very satisfied17.950.0
Cycle 7 Day 15: satisfied53.846.3
Cycle 8 Day 15: very satisfied20.045.1
Cycle 8 Day 15: satisfied46.746.9
Cycle 9 Day 15: very satisfied24.150.7
Cycle 9 Day 15: satisfied47.545.1
Cycle 10 Day 15: very satisfied21.353.3
Cycle 10 Day 15: satisfied46.040.7
Cycle 11 Day 15: very satisfied21.356.0
Cycle 11 Day 15: satisfied46.739.0
Cycle 12 Day 15: very satisfied20.655.6
Cycle 12 Day 15: satisfied51.140.0
Cycle 13 Day 15: very satisfied23.248.8
Cycle 13 Day 15: satisfied50.447.2
Cycle 14 Day 15: very satisfied23.651.2
Cycle 14 Day 15: satisfied46.343.2
Cycle 15 Day 15: very satisfied26.353.9
Cycle 15 Day 15: satisfied48.241.7
Cycle 16 Day 15: very satisfied24.058.3
Cycle 16 Day 15: satisfied50.038.0
Cycle 17 Day 15: very satisfied27.754.7
Cycle 17 Day 15: satisfied47.941.1
Cycle 18 Day 15: very satisfied30.247.6
Cycle 18 Day 15: satisfied50.047.6
Cycle 19 Day 15: very satisfied17.853.5
Cycle 19 Day 15: satisfied56.240.8
Cycle 20 Day 15: very satisfied20.756.1
Cycle 20 Day 15: satisfied50.038.6
Cycle 21 Day 15: very satisfied14.570.2
Cycle 21 Day 15: satisfied49.129.8
Cycle 22 Day 15: very satisfied19.653.7
Cycle 22 Day 15: satisfied54.943.9
Cycle 23 Day 15: very satisfied25.058.3
Cycle 23 Day 15: satisfied55.041.7
Cycle 24 Day 15: very satisfied22.054.8
Cycle 24 Day 15: satisfied53.745.2
Cycle 25 Day 15: very satisfied22.953.8
Cycle 25 Day 15: satisfied54.342.3
Cycle 26 Day 15: very satisfied21.456.0
Cycle 26 Day 15: satisfied60.744.0
Cycle 27 Day 15: very satisfied26.160.0
Cycle 27 Day 15: satisfied60.933.3
Cycle 28 Day 15: very satisfied37.564.3
Cycle 28 Day 15: satisfied56.335.7
Cycle 29 Day 15: very satisfied37.561.5
Cycle 29 Day 15: satisfied50.038.5
Cycle 30 Day 15: very satisfied28.655.6
Cycle 30 Day 15: satisfied64.344.4
Cycle 31 Day 15: very satisfied66.766.7
Cycle 31 Day 15: satisfied22.233.3
Cycle 32 Day 15: very satisfied37.550.0
Cycle 32 Day 15: satisfied50.050.0
Cycle 33 Day 15: very satisfied33.366.7
Cycle 33 Day 15: satisfied66.733.3
Cycle 34 Day 15: very satisfied25.050.0
Cycle 34 Day 15: satisfied75.050.0
Cycle 35 Day 15: very satisfied50.033.3
Cycle 35 Day 15: satisfied50.066.7
Cycle 36 Day 15: very satisfied033.3
Cycle 36 Day 15: satisfied10066.7
Cycle 37 Day 15: very satisfied050.0
Cycle 37 Day 15: satisfied10050.0
Cycle 38 Day 15: very satisfied050.0
Cycle 38 Day 15: satisfied10050.0
Cycle 39 Day 15: very satisfied—0
Cycle 39 Day 15: satisfied—100
SecondaryPercentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Side Effects With Study Medication'

The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'side effects with study medication' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who disagreed and strongly disagreed that they experienced any side effects with study medication are reported here. Percentages are rounded off to the tenth decimal place.

Time frame:
Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Disagreed and Strongly Disagreed to 'PESQ-FU: Side Effects With Study Medication'
percentage of participantsIsa-IV + PdIsa-SC + Pd
Cycle 1 Day 8: disagree35.045.0
Cycle 1 Day 8: strongly disagree16.124.8
Cycle 1 Day 15: disagree38.638.3
Cycle 1 Day 15: strongly disagree12.923.8
Cycle 1 Day 22: disagree41.040.2
Cycle 1 Day 22: strongly disagree9.420.1
Cycle 2 Day 1: disagree38.247.1
Cycle 2 Day 1: strongly disagree9.022.9
Cycle 2 Day 15: disagree41.647.4
Cycle 2 Day 15: strongly disagree10.420.4
Cycle 3 Day 1: disagree40.840.7
Cycle 3 Day 1: strongly disagree11.026.4
Cycle 4 Day 1: disagree40.148.4
Cycle 4 Day 1: strongly disagree11.323.7
Cycle 5 Day 15: disagree39.745.6
Cycle 5 Day 15: strongly disagree12.326.9
Cycle 6 Day 15: disagree39.144.2
Cycle 6 Day 15: strongly disagree13.828.5
Cycle 7 Day 15: disagree38.244.5
Cycle 7 Day 15: strongly disagree15.632.3
Cycle 8 Day 15: disagree33.343.2
Cycle 8 Day 15: strongly disagree18.230.2
Cycle 9 Day 15: disagree31.043.1
Cycle 9 Day 15: strongly disagree20.333.3
Cycle 10 Day 15: disagree39.338.0
Cycle 10 Day 15: strongly disagree18.739.3
Cycle 11 Day 15: disagree38.036.2
Cycle 11 Day 15: strongly disagree18.737.6
Cycle 12 Day 15: disagree37.447.4
Cycle 12 Day 15: strongly disagree15.330.4
Cycle 13 Day 15: disagree36.840.7
Cycle 13 Day 15: strongly disagree16.035.0
Cycle 14 Day 15: disagree35.846.4
Cycle 14 Day 15: strongly disagree16.331.2
Cycle 15 Day 15: disagree35.137.4
Cycle 15 Day 15: strongly disagree20.237.4
Cycle 16 Day 15: disagree26.037.0
Cycle 16 Day 15: strongly disagree20.237.0
Cycle 17 Day 15: disagree34.040.0
Cycle 17 Day 15: strongly disagree21.338.9
Cycle 18 Day 15: disagree37.234.5
Cycle 18 Day 15: strongly disagree19.841.7
Cycle 19 Day 15: disagree28.836.6
Cycle 19 Day 15: strongly disagree19.239.4
Cycle 20 Day 15: disagree22.440.4
Cycle 20 Day 15: strongly disagree24.136.8
Cycle 21 Day 15: disagree40.038.3
Cycle 21 Day 15: strongly disagree10.946.8
Cycle 22 Day 15: disagree39.241.5
Cycle 22 Day 15: strongly disagree17.643.9
Cycle 23 Day 15: disagree37.536.1
Cycle 23 Day 15: strongly disagree17.541.7
Cycle 24 Day 15: disagree31.748.4
Cycle 24 Day 15: strongly disagree19.535.5
Cycle 25 Day 15: disagree31.438.5
Cycle 25 Day 15: strongly disagree25.742.3
Cycle 26 Day 15: disagree28.644.0
Cycle 26 Day 15: strongly disagree32.140.0
Cycle 27 Day 15: disagree30.426.7
Cycle 27 Day 15: strongly disagree30.446.7
Cycle 28 Day 15: disagree31.342.9
Cycle 28 Day 15: strongly disagree37.542.9
Cycle 29 Day 15: disagree50.038.5
Cycle 29 Day 15: strongly disagree18.846.2
Cycle 30 Day 15: disagree35.744.4
Cycle 30 Day 15: strongly disagree42.944.4
Cycle 31 Day 15: disagree55.633.3
Cycle 31 Day 15: strongly disagree22.233.3
Cycle 32 Day 15: disagree37.525.0
Cycle 32 Day 15: strongly disagree12.525.0
Cycle 33 Day 15: disagree33.316.7
Cycle 33 Day 15: strongly disagree33.350.0
Cycle 34 Day 15: disagree25.050.0
Cycle 34 Day 15: strongly disagree25.025.0
Cycle 35 Day 15: disagree25.0100
Cycle 35 Day 15: strongly disagree25.00
Cycle 36 Day 15: disagree50.033.3
Cycle 36 Day 15: strongly disagree50.00
Cycle 37 Day 15: disagree50.050.0
Cycle 37 Day 15: strongly disagree50.00
Cycle 38 Day 15: disagree0100
Cycle 38 Day 15: strongly disagree1000
Cycle 39 Day 15: disagree—0
Cycle 39 Day 15: strongly disagree—0
SecondaryPercentage of Participants Who Strongly Agreed and Agreed to 'PESQ-FU: Study Medication Worth Taking'

The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'study medication worth taking' were recorded as 'strongly agree, agree, neither agree nor disagree, disagree and strongly disagree' at specified timepoints. Percentage of participants who strongly agreed and agreed that the study medication was worth taking are reported here. Percentages are rounded off to the tenth decimal place.

Time frame:
Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Strongly Agreed and Agreed to 'PESQ-FU: Study Medication Worth Taking'
percentage of participantsIsa-IV + PdIsa-SC + Pd
Cycle 1 Day 8: strongly agree18.033.8
Cycle 1 Day 8: agree48.442.3
Cycle 1 Day 15: strongly agree19.532.0
Cycle 1 Day 15: agree51.949.5
Cycle 1 Day 22: strongly agree20.830.6
Cycle 1 Day 22: agree45.846.9
Cycle 2 Day 1: strongly agree21.034.4
Cycle 2 Day 1: agree48.946.7
Cycle 2 Day 15: strongly agree21.731.8
Cycle 2 Day 15: agree50.251.2
Cycle 3 Day 1: strongly agree20.641.7
Cycle 3 Day 1: agree52.846.8
Cycle 4 Day 1: strongly agree23.139.5
Cycle 4 Day 1: agree54.747.0
Cycle 5 Day 15: strongly agree25.543.5
Cycle 5 Day 15: agree49.549.7
Cycle 6 Day 15: strongly agree25.941.9
Cycle 6 Day 15: agree50.048.3
Cycle 7 Day 15: strongly agree27.744.5
Cycle 7 Day 15: agree52.645.7
Cycle 8 Day 15: strongly agree28.542.0
Cycle 8 Day 15: agree47.350.0
Cycle 9 Day 15: strongly agree33.543.1
Cycle 9 Day 15: agree45.647.2
Cycle 10 Day 15: strongly agree30.045.3
Cycle 10 Day 15: agree45.346.7
Cycle 11 Day 15: strongly agree30.049.6
Cycle 11 Day 15: agree48.741.1
Cycle 12 Day 15: strongly agree27.548.9
Cycle 12 Day 15: agree51.945.2
Cycle 13 Day 15: strongly agree34.441.5
Cycle 13 Day 15: agree47.252.0
Cycle 14 Day 15: strongly agree35.840.0
Cycle 14 Day 15: agree44.751.2
Cycle 15 Day 15: strongly agree32.547.8
Cycle 15 Day 15: agree43.947.8
Cycle 16 Day 15: strongly agree39.449.1
Cycle 16 Day 15: agree45.245.4
Cycle 17 Day 15: strongly agree39.449.5
Cycle 17 Day 15: agree40.445.3
Cycle 18 Day 15: strongly agree32.647.6
Cycle 18 Day 15: agree51.244.0
Cycle 19 Day 15: strongly agree31.549.3
Cycle 19 Day 15: agree49.340.8
Cycle 20 Day 15: strongly agree36.254.4
Cycle 20 Day 15: agree41.440.4
Cycle 21 Day 15: strongly agree23.661.7
Cycle 21 Day 15: agree58.236.2
Cycle 22 Day 15: strongly agree31.451.2
Cycle 22 Day 15: agree49.048.8
Cycle 23 Day 15: strongly agree27.555.6
Cycle 23 Day 15: agree52.544.4
Cycle 24 Day 15: strongly agree41.551.6
Cycle 24 Day 15: agree46.348.4
Cycle 25 Day 15: strongly agree34.350.0
Cycle 25 Day 15: agree54.350.0
Cycle 26 Day 15: strongly agree46.460.0
Cycle 26 Day 15: agree46.440.0
Cycle 27 Day 15: strongly agree52.253.3
Cycle 27 Day 15: agree34.846.7
Cycle 28 Day 15: strongly agree50.057.1
Cycle 28 Day 15: agree37.535.7
Cycle 29 Day 15: strongly agree37.553.8
Cycle 29 Day 15: agree56.346.2
Cycle 30 Day 15: strongly agree71.466.7
Cycle 30 Day 15: agree21.433.3
Cycle 31 Day 15: strongly agree77.866.7
Cycle 31 Day 15: agree11.133.3
Cycle 32 Day 15: strongly agree75.075.0
Cycle 32 Day 15: agree12.525.0
Cycle 33 Day 15: strongly agree50.050.0
Cycle 33 Day 15: agree50.050.0
Cycle 34 Day 15: strongly agree50.075.0
Cycle 34 Day 15: agree50.025.0
Cycle 35 Day 15: strongly agree25.033.3
Cycle 35 Day 15: agree75.066.7
Cycle 36 Day 15: strongly agree033.3
Cycle 36 Day 15: agree10066.7
Cycle 37 Day 15: strongly agree50.050.0
Cycle 37 Day 15: agree50.050.0
Cycle 38 Day 15: strongly agree10050.0
Cycle 38 Day 15: agree050.0
Cycle 39 Day 15: strongly agree—0
Cycle 39 Day 15: agree—100
SecondaryPercentage of Participants Who Responded Very Satisfied and Satisfied to 'PESQ-FU: Satisfaction With Study Medication'

The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to satisfaction with study medication were recorded as 'very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and very dissatisfied' at specified timepoints. Percentage of participants who were very satisfied and satisfied with the study medication are reported here. Percentages are rounded off to the tenth decimal place.

Time frame:
Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Responded Very Satisfied and Satisfied to 'PESQ-FU: Satisfaction With Study Medication'
percentage of participantsIsa-IV + PdIsa-SC + Pd
Cycle 1 Day 8: very satisfied17.129.3
Cycle 1 Day 8: satisfied55.850.9
Cycle 1 Day 15: very satisfied21.030.6
Cycle 1 Day 15: satisfied48.148.1
Cycle 1 Day 22: very satisfied16.030.1
Cycle 1 Day 22: satisfied58.048.8
Cycle 2 Day 1: very satisfied18.931.3
Cycle 2 Day 1: satisfied53.650.2
Cycle 2 Day 15: very satisfied20.830.3
Cycle 2 Day 15: satisfied57.052.6
Cycle 3 Day 1: very satisfied19.338.0
Cycle 3 Day 1: satisfied61.549.5
Cycle 4 Day 1: very satisfied21.237.7
Cycle 4 Day 1: satisfied59.950.2
Cycle 5 Day 15: very satisfied27.546.1
Cycle 5 Day 15: satisfied54.946.1
Cycle 6 Day 15: very satisfied27.041.9
Cycle 6 Day 15: satisfied55.745.3
Cycle 7 Day 15: very satisfied32.945.7
Cycle 7 Day 15: satisfied49.148.8
Cycle 8 Day 15: very satisfied33.344.4
Cycle 8 Day 15: satisfied49.747.5
Cycle 9 Day 15: very satisfied39.948.6
Cycle 9 Day 15: satisfied45.645.1
Cycle 10 Day 15: very satisfied34.747.3
Cycle 10 Day 15: satisfied48.744.0
Cycle 11 Day 15: very satisfied33.348.9
Cycle 11 Day 15: satisfied52.044.0
Cycle 12 Day 15: very satisfied32.849.6
Cycle 12 Day 15: satisfied53.443.7
Cycle 13 Day 15: very satisfied37.651.2
Cycle 13 Day 15: satisfied48.843.1
Cycle 14 Day 15: very satisfied39.044.0
Cycle 14 Day 15: satisfied49.647.2
Cycle 15 Day 15: very satisfied36.851.3
Cycle 15 Day 15: satisfied48.244.3
Cycle 16 Day 15: very satisfied45.253.7
Cycle 16 Day 15: satisfied43.339.8
Cycle 17 Day 15: very satisfied38.353.7
Cycle 17 Day 15: satisfied45.742.1
Cycle 18 Day 15: very satisfied39.553.6
Cycle 18 Day 15: satisfied52.339.3
Cycle 19 Day 15: very satisfied35.653.5
Cycle 19 Day 15: satisfied50.739.4
Cycle 20 Day 15: very satisfied41.449.1
Cycle 20 Day 15: satisfied44.843.9
Cycle 21 Day 15: very satisfied40.068.1
Cycle 21 Day 15: satisfied47.327.7
Cycle 22 Day 15: very satisfied37.348.8
Cycle 22 Day 15: satisfied51.046.3
Cycle 23 Day 15: very satisfied32.550.0
Cycle 23 Day 15: satisfied52.550.0
Cycle 24 Day 15: very satisfied41.548.4
Cycle 24 Day 15: satisfied46.348.4
Cycle 25 Day 15: very satisfied40.057.7
Cycle 25 Day 15: satisfied45.742.3
Cycle 26 Day 15: very satisfied46.464.0
Cycle 26 Day 15: satisfied42.936.0
Cycle 27 Day 15: very satisfied43.560.0
Cycle 27 Day 15: satisfied47.833.3
Cycle 28 Day 15: very satisfied50.064.3
Cycle 28 Day 15: satisfied43.828.6
Cycle 29 Day 15: very satisfied56.353.8
Cycle 29 Day 15: satisfied37.546.2
Cycle 30 Day 15: very satisfied50.066.7
Cycle 30 Day 15: satisfied42.933.3
Cycle 31 Day 15: very satisfied77.866.7
Cycle 31 Day 15: satisfied11.133.3
Cycle 32 Day 15: very satisfied75.075.0
Cycle 32 Day 15: satisfied12.525.0
Cycle 33 Day 15: very satisfied50.066.7
Cycle 33 Day 15: satisfied50.033.3
Cycle 34 Day 15: very satisfied50.050.0
Cycle 34 Day 15: satisfied50.050.0
Cycle 35 Day 15: very satisfied50.033.3
Cycle 35 Day 15: satisfied50.066.7
Cycle 36 Day 15: very satisfied50.033.3
Cycle 36 Day 15: satisfied50.066.7
Cycle 37 Day 15: very satisfied050.0
Cycle 37 Day 15: satisfied10050.0
Cycle 38 Day 15: very satisfied10050.0
Cycle 38 Day 15: satisfied050.0
Cycle 39 Day 15: very satisfied—0
Cycle 39 Day 15: satisfied—100
SecondaryPercentage of Participants Who Responded Definitely Yes and Probably Yes to 'PESQ-FU: Recommendation of Study Medication'

The PESQ-FU consisting of 9 items has been designed to follow up on participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation). This questionnaire has been adapted based on qualitative interviews with oncology participants. The responses to 'recommendation of the study medication' were recorded as 'definitely yes, probably yes, unsure, probably not and definitely not' at specified timepoints. Percentage of participants who responded definitely yes and probably yes to the recommendation of study medication are reported here. Percentages are rounded off to the tenth decimal place.

Time frame:
Cycle 1 Days 8, 15, 22, Cycle 2 Days 1 and 15, Cycles 3 and 4 Day 1, Cycles 5 to 39 Day 15
Reported as:
Number · percentage of participants
Percentage of Participants Who Responded Definitely Yes and Probably Yes to 'PESQ-FU: Recommendation of Study Medication'
percentage of participantsIsa-IV + PdIsa-SC + Pd
Cycle 1 Day 8: definitely yes24.450.5
Cycle 1 Day 8: probably yes43.334.7
Cycle 1 Day 15: definitely yes30.046.1
Cycle 1 Day 15: probably yes44.337.9
Cycle 1 Day 22: definitely yes26.945.9
Cycle 1 Day 22: probably yes46.739.7
Cycle 2 Day 1: definitely yes25.849.8
Cycle 2 Day 1: probably yes42.936.6
Cycle 2 Day 15: definitely yes27.147.9
Cycle 2 Day 15: probably yes46.638.9
Cycle 3 Day 1: definitely yes28.453.2
Cycle 3 Day 1: probably yes48.636.6
Cycle 4 Day 1: definitely yes29.752.6
Cycle 4 Day 1: probably yes50.038.6
Cycle 5 Day 15: definitely yes33.859.6
Cycle 5 Day 15: probably yes47.534.2
Cycle 6 Day 15: definitely yes33.956.4
Cycle 6 Day 15: probably yes46.039.0
Cycle 7 Day 15: definitely yes32.959.8
Cycle 7 Day 15: probably yes45.735.4
Cycle 8 Day 15: definitely yes43.056.2
Cycle 8 Day 15: probably yes35.837.7
Cycle 9 Day 15: definitely yes39.959.7
Cycle 9 Day 15: probably yes41.137.5
Cycle 10 Day 15: definitely yes42.063.3
Cycle 10 Day 15: probably yes40.030.7
Cycle 11 Day 15: definitely yes41.363.1
Cycle 11 Day 15: probably yes38.029.8
Cycle 12 Day 15: definitely yes38.960.0
Cycle 12 Day 15: probably yes35.934.1
Cycle 13 Day 15: definitely yes40.061.8
Cycle 13 Day 15: probably yes36.831.7
Cycle 14 Day 15: definitely yes41.560.0
Cycle 14 Day 15: probably yes35.032.0
Cycle 15 Day 15: definitely yes45.658.3
Cycle 15 Day 15: probably yes35.133.9
Cycle 16 Day 15: definitely yes46.260.2
Cycle 16 Day 15: probably yes37.532.4
Cycle 17 Day 15: definitely yes51.154.7
Cycle 17 Day 15: probably yes24.536.8
Cycle 18 Day 15: definitely yes39.563.1
Cycle 18 Day 15: probably yes40.729.8
Cycle 19 Day 15: definitely yes35.660.6
Cycle 19 Day 15: probably yes39.733.8
Cycle 20 Day 15: definitely yes50.064.9
Cycle 20 Day 15: probably yes25.929.8
Cycle 21 Day 15: definitely yes38.270.2
Cycle 21 Day 15: probably yes34.525.5
Cycle 22 Day 15: definitely yes39.265.9
Cycle 22 Day 15: probably yes37.326.8
Cycle 23 Day 15: definitely yes47.569.4
Cycle 23 Day 15: probably yes27.527.8
Cycle 24 Day 15: definitely yes43.958.1
Cycle 24 Day 15: probably yes31.738.7
Cycle 25 Day 15: definitely yes48.669.2
Cycle 25 Day 15: probably yes28.626.9
Cycle 26 Day 15: definitely yes39.372.0
Cycle 26 Day 15: probably yes46.424.0
Cycle 27 Day 15: definitely yes39.160.0
Cycle 27 Day 15: probably yes39.126.7
Cycle 28 Day 15: definitely yes56.357.1
Cycle 28 Day 15: probably yes31.328.6
Cycle 29 Day 15: definitely yes56.361.5
Cycle 29 Day 15: probably yes25.030.8
Cycle 30 Day 15: definitely yes71.466.7
Cycle 30 Day 15: probably yes7.122.2
Cycle 31 Day 15: definitely yes77.866.7
Cycle 31 Day 15: probably yes11.116.7
Cycle 32 Day 15: definitely yes75.050.0
Cycle 32 Day 15: probably yes12.525.0
Cycle 33 Day 15: definitely yes66.750.0
Cycle 33 Day 15: probably yes33.333.3
Cycle 34 Day 15: definitely yes50.050.0
Cycle 34 Day 15: probably yes50.025.0
Cycle 35 Day 15: definitely yes50.033.3
Cycle 35 Day 15: probably yes50.033.3
Cycle 36 Day 15: definitely yes50.033.3
Cycle 36 Day 15: probably yes50.033.3
Cycle 37 Day 15: definitely yes50.050.0
Cycle 37 Day 15: probably yes50.00
Cycle 38 Day 15: definitely yes10050.0
Cycle 38 Day 15: probably yes00
Cycle 39 Day 15: definitely yes—0
Cycle 39 Day 15: probably yes—0
SecondaryPercentage of Participants With Response to 'Patient Experience and Satisfaction End of Treatment Questionnaire (PESQ-EOT)'

The PESQ-EOT consisting of 17 items assessed participant experience and satisfaction regarding the injection method (discomfort, pain, side effects, time saving and satisfaction) and study medication (side effects, worth taking, satisfaction and recommendation) and has been adapted based on qualitative interviews with oncology participants. In addition to the above, this questionnaire also includes additional items to assess whether participants received oncology medications in the past 2 years and if a participant received both IV and SC in the past 2 years, then participant preference on injection method (whether SC or IV). Percentage of participants with response to these additional items (received oncology medications in the past 2 years via IV/SC/both and if received both IV and SC; then the participant preference on injection method) are reported here. Percentages are rounded off to the tenth decimal place.

Time frame:
EOT visit (up to DCO date: 29-Aug-2025) (30 days after last study medication administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 38 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Response to 'Patient Experience and Satisfaction End of Treatment Questionnaire (PESQ-EOT)'
percentage of participantsIsa-IV + PdIsa-SC + Pd
Received oncology medications in the past 2 years via IV only59.425.7
Received oncology medications in the past 2 years via SC only9.431.9
Received oncology medications in the past 2 years via both IV and SC13.218.6
If received via both IV and SC: Preference for injection method: IV7.10
If received via both IV and SC: Preference for injection method: SC57.190.5
If received via both IV and SC: No preference for injection method35.79.5
SecondaryParticipant Responses to Patient's Assessment of Treatment (PAT) Questionnaire

The 4-item PAT is an internally developed non-disease specific and self-administered assessment which has been debriefed with oncology patients during qualitative interviews. It provided participant insights on the benefits and disadvantages of treatment. Benefits and disadvantages were respectively rated on a 0-10 scale wherein 0=none (not beneficial at all or no disadvantages at all) and 10=maximum (extremely beneficial or extremely disadvantageous). Disadvantages vs benefits were rated on a scale of -3 to 3 wherein -3=disadvantages significantly outweigh the benefits, 0=equal benefits and disadvantages and 3=benefits significantly outweigh the disadvantages. Mean of benefits, disadvantages and disadvantages vs benefits is presented here.

Time frame:
EOT visit (up to DCO date: 29-Aug-2025) (30 days after last study medication administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 38 months)
Reported as:
Mean · score on a scale
Participant Responses to Patient's Assessment of Treatment (PAT) Questionnaire
score on a scaleIsa-IV + PdIsa-SC + Pd
Benefits6.1 ± 2.46.6 ± 2.3
Disadvantages4.0 ± 2.73.4 ± 2.6
Disadvantages vs benefits0.7 ± 1.91.4 ± 1.8
SecondaryHealth Resource Utilization and Productivity Questionnaire (HRUPQ): Baseline Healthcare Utilization: Number of Times in the Past 6 Months a Participant Received Care

Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of times in the past 6 months a participant received care in a clinic or hospital emergency room for any health issue including MM or due to MM and at-home care from a nurse or other health professional for any health issue including MM or due to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1)
Reported as:
Mean · number of times received care
Health Resource Utilization and Productivity Questionnaire (HRUPQ): Baseline Healthcare Utilization: Number of Times in the Past 6 Months a Participant Received Care
number of times received careIsa-IV + PdIsa-SC + Pd
In a clinic or hospital emergency room for any health issue including MM3.6 ± 3.63.7 ± 4.1
In a clinic or hospital emergency room due to MM4.4 ± 3.34.2 ± 4.2
At-home from nurse or other health professional for any health issue including MM4.4 ± 5.43.8 ± 3.2
At-home from nurse or other health professional due to MM4.7 ± 5.93.9 ± 3.6
SecondaryHRUPQ: Baseline Healthcare Utilization: Number of Nights in the Past 6 Months a Participant Stayed in Hospital

Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of nights in the past 6 month a participant stayed in hospital for any health issue including MM or due to MM and stayed in intensive care unit (ICU) for any health issue including MM or due to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1)
Reported as:
Mean · number of nights
HRUPQ: Baseline Healthcare Utilization: Number of Nights in the Past 6 Months a Participant Stayed in Hospital
number of nightsIsa-IV + PdIsa-SC + Pd
Stayed in hospital for any health issue including MM7.2 ± 12.35.2 ± 9.0
Stayed in hospital due to MM10.3 ± 20.26.5 ± 10.3
Stayed in ICU for any health issue including MM5.0 ± 2.61.3 ± 0.5
Stayed in ICU due to MM—3.0 ± 2.0
SecondaryHRUPQ: Baseline Healthcare Utilization: Number of Times in the Past 6 Months a Participant Consulted a Healthcare Professional (HCP)

Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of times in the past 6 months a participant consulted (had seen or talked to) following healthcare professionals: general doctor or primary care clinician (PCC) who treats a variety of illnesses for any health issue including MM or related to MM, physical or occupational therapist for any health issue including MM or related to MM, mental health professional (e.g. psychiatrist, psychologist, psychiatric nurse) for any health issue including MM or related to MM, medical doctor or clinician who specializes in particular medical disease or issue (specialist) for any health issue including MM or related to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1)
Reported as:
Mean · number of times consulted a HCP
HRUPQ: Baseline Healthcare Utilization: Number of Times in the Past 6 Months a Participant Consulted a Healthcare Professional (HCP)
number of times consulted a HCPIsa-IV + PdIsa-SC + Pd
General doctor or PCC for any health issue including MM4.5 ± 3.94.9 ± 5.4
General doctor or PCC for health issue related to MM4.5 ± 3.95.3 ± 7.6
Physical or occupational therapist for any health issue including MM6.3 ± 5.36.7 ± 9.7
Physical or occupational therapist for health issue related to MM6.2 ± 5.45.0 ± 6.4
Mental health professional for any health issue including MM3.2 ± 3.05.2 ± 7.4
Mental health professional for health issue related to MM3.3 ± 2.44.4 ± 7.8
Medical doctor or clinician (specialist) for any health issue including MM4.2 ± 3.14.4 ± 3.3
Medical doctor or clinician (specialist) for health issue related to MM4.5 ± 3.04.2 ± 2.4
SecondaryDuration of Hospital Visits for Treatment Administration and Duration of Post-Treatment Monitoring Based on HRUPQ

Medical resource utilization was collected through HRUPQ. Participants were asked to indicate the duration of their hospital visit (from arrival to departure) and the duration of post-treatment monitoring based on their most recent isatuximab administration. The median duration across all visits (starting from Cycle 2) was calculated and reported here.

Time frame:
From Cycle 2 Day 1 up to EOT visit (up to PCD: 06-Nov-2024) (30 days after last study medication administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 28 months)
Reported as:
Median · minutes
Duration of Hospital Visits for Treatment Administration and Duration of Post-Treatment Monitoring Based on HRUPQ
minutesIsa-IV + PdIsa-SC + Pd
Duration of hospital visit240.00 (1.0 to 500.0)180.00 (1.0 to 600.0)
Duration of post-treatment monitoring30.00 (1.0 to 500.0)30.00 (1.0 to 500.0)
SecondaryPercentage of Participants Who Visited Healthcare Professional for Non-trial-related Health Issues Based on HRUPQ

Medical resource utilization was collected through HRUPQ. Percentage of participants with healthcare professional visit not required by clinical trial since last isatuximab administration was recorded. Percentages are rounded off to the tenth decimal place.

Time frame:
Cycle 1 Days 8, 15 and 22, Cycle 2 Day 1, Cycles 3 to 29 Day 15 and EOT visit (up to PCD: 06-Nov-2024) (30 days after last drug administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 28 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Visited Healthcare Professional for Non-trial-related Health Issues Based on HRUPQ
percentage of participantsIsa-IV + PdIsa-SC + Pd
Cycle 1 Day 811.414.9
Cycle 1 Day 1510.09.2
Cycle 1 Day 2211.79.8
Cycle 2 Day 112.510.8
Cycle 3 Day 1513.211.5
Cycle 4 Day 1513.18.5
Cycle 5 Day 158.97.3
Cycle 6 Day 159.79.2
Cycle 7 Day 1513.29.2
Cycle 8 Day 1516.714.6
Cycle 9 Day 1511.614.1
Cycle 10 Day 1510.914.1
Cycle 11 Day 1513.010.4
Cycle 12 Day 156.810.9
Cycle 13 Day 1516.912.3
Cycle 14 Day 1512.55.8
Cycle 15 Day 1518.812.5
Cycle 16 Day 157.513.9
Cycle 17 Day 1515.216.7
Cycle 18 Day 1513.012.0
Cycle 19 Day 158.313.6
Cycle 20 Day 1512.515.8
Cycle 21 Day 1525.00
Cycle 22 Day 1544.411.1
Cycle 23 Day 15022.2
Cycle 24 Day 1520.00
Cycle 25 Day 15025.0
Cycle 26 Day 1500
Cycle 27 Day 1500
Cycle 28 Day 15—50.0
Cycle 29 Day 15—0
EOT visit25.017.1
SecondaryPercentage of Participants Who Ever Retired During the Study Based on HRUPQ

Employment status was assessed via HRUPQ. Percentage of participants who ever retired during the study are reported. Percentages are rounded off to the tenth decimal place.

Time frame:
From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Ever Retired During the Study Based on HRUPQ
percentage of participantsIsa-IV + PdIsa-SC + Pd
Percentage of Participants Who Ever Retired During the Study Based on HRUPQ81.783.6
SecondaryPercentage of Participants Who Retired Early Due to MM Based on HRUPQ

Employment status was assessed via HRUPQ. Percentage of participants who retired early due to MM are reported. Percentages are rounded off to the tenth decimal place.

Time frame:
From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Retired Early Due to MM Based on HRUPQ
percentage of participantsIsa-IV + PdIsa-SC + Pd
Percentage of Participants Who Retired Early Due to MM Based on HRUPQ32.037.3
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QoL)

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For GHS/QoL: overall health and quality of life were assessed, rated on a 7-point scale (1: very poor to 7: excellent). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for GHS/QoL and a positive change from baseline represents a healthy/better level of QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QoL)
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 1-2.75 ± 18.66-1.50 ± 17.72
Cycle 3 Day 15-0.56 ± 19.15-0.23 ± 18.05
Cycle 4 Day 15-0.05 ± 19.161.41 ± 19.37
Cycle 5 Day 150.65 ± 18.491.42 ± 20.67
Cycle 6 Day 150.06 ± 18.403.17 ± 19.52
Cycle 7 Day 15-0.23 ± 21.413.15 ± 20.62
Cycle 8 Day 151.88 ± 16.650.43 ± 19.75
Cycle 9 Day 15-0.19 ± 20.031.13 ± 20.32
Cycle 10 Day 150.21 ± 18.833.05 ± 20.61
Cycle 11 Day 15-1.03 ± 19.291.06 ± 20.34
Cycle 12 Day 15-0.31 ± 18.912.65 ± 21.08
Cycle 13 Day 150.89 ± 19.734.63 ± 18.57
Cycle 14 Day 150.25 ± 19.691.43 ± 21.35
Cycle 15 Day 15-0.61 ± 20.100.17 ± 20.62
Cycle 16 Day 151.18 ± 17.162.51 ± 21.13
Cycle 17 Day 15-0.32 ± 17.971.19 ± 20.46
Cycle 18 Day 15-1.35 ± 19.880.60 ± 19.78
Cycle 19 Day 15-1.88 ± 19.050.14 ± 22.24
Cycle 20 Day 15-0.63 ± 17.67-0.54 ± 21.33
Cycle 21 Day 150.33 ± 19.003.07 ± 21.17
Cycle 22 Day 153.99 ± 16.834.55 ± 20.21
Cycle 23 Day 150.23 ± 17.196.32 ± 23.53
Cycle 24 Day 155.26 ± 17.278.33 ± 21.42
Cycle 25 Day 156.18 ± 19.006.67 ± 23.97
Cycle 26 Day 155.21 ± 20.384.39 ± 16.75
Cycle 27 Day 1511.67 ± 17.1816.03 ± 27.74
Cycle 28 Day 159.44 ± 15.399.17 ± 27.62
Cycle 29 Day 158.33 ± 13.4814.17 ± 32.64
Cycle 30 Day 159.72 ± 9.955.95 ± 12.47
EOT-5.62 ± 21.42-3.25 ± 21.64
SecondaryChange From Baseline in EORTC QLQ-C30: Physical Functioning

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of physical functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Physical Functioning
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 1-1.67 ± 17.24-2.50 ± 15.85
Cycle 3 Day 15-1.98 ± 15.74-0.67 ± 17.01
Cycle 4 Day 15-0.98 ± 14.62-1.20 ± 18.63
Cycle 5 Day 15-1.41 ± 15.23-0.33 ± 18.25
Cycle 6 Day 15-1.05 ± 14.790.84 ± 17.45
Cycle 7 Day 15-1.94 ± 15.08-0.42 ± 17.82
Cycle 8 Day 15-0.60 ± 15.540.59 ± 18.81
Cycle 9 Day 15-2.77 ± 16.010.34 ± 18.40
Cycle 10 Day 15-1.21 ± 15.300.81 ± 19.02
Cycle 11 Day 15-2.37 ± 14.730.11 ± 18.43
Cycle 12 Day 15-0.87 ± 12.950.41 ± 19.32
Cycle 13 Day 15-1.29 ± 13.50-1.48 ± 19.60
Cycle 14 Day 15-1.89 ± 12.01-0.32 ± 18.68
Cycle 15 Day 15-3.33 ± 14.480.00 ± 23.19
Cycle 16 Day 15-1.65 ± 16.36-0.07 ± 18.89
Cycle 17 Day 15-2.87 ± 14.11-2.54 ± 21.31
Cycle 18 Day 15-4.71 ± 17.32-2.29 ± 20.52
Cycle 19 Day 15-3.98 ± 15.99-2.26 ± 18.96
Cycle 20 Day 15-2.89 ± 15.11-2.32 ± 19.02
Cycle 21 Day 15-4.97 ± 15.022.98 ± 20.19
Cycle 22 Day 15-3.62 ± 16.013.64 ± 18.11
Cycle 23 Day 15-6.67 ± 15.94-2.30 ± 24.38
Cycle 24 Day 15-4.21 ± 17.291.67 ± 24.42
Cycle 25 Day 15-4.73 ± 17.14-1.67 ± 22.98
Cycle 26 Day 15-2.50 ± 19.24-2.11 ± 16.93
Cycle 27 Day 152.67 ± 15.814.62 ± 26.02
Cycle 28 Day 15-0.44 ± 13.684.67 ± 23.94
Cycle 29 Day 15-0.48 ± 13.455.33 ± 23.26
Cycle 30 Day 155.00 ± 15.86-0.95 ± 15.12
EOT-8.76 ± 21.78-7.60 ± 20.03
SecondaryChange From Baseline in EORTC QLQ-C30: Role Functioning

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of role functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Role Functioning
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 1-4.79 ± 22.56-1.75 ± 24.86
Cycle 3 Day 15-2.42 ± 22.86-1.12 ± 27.08
Cycle 4 Day 15-0.75 ± 22.431.65 ± 26.71
Cycle 5 Day 15-2.71 ± 20.70-0.41 ± 28.89
Cycle 6 Day 15-1.83 ± 21.720.44 ± 27.58
Cycle 7 Day 15-2.66 ± 22.792.80 ± 29.80
Cycle 8 Day 15-1.63 ± 20.50-2.22 ± 32.37
Cycle 9 Day 15-4.23 ± 21.40-2.54 ± 31.25
Cycle 10 Day 15-3.72 ± 19.662.17 ± 28.79
Cycle 11 Day 15-2.48 ± 18.84-1.98 ± 31.74
Cycle 12 Day 15-2.34 ± 18.94-0.29 ± 30.62
Cycle 13 Day 15-3.72 ± 18.51-1.52 ± 28.78
Cycle 14 Day 15-6.73 ± 18.28-2.70 ± 30.15
Cycle 15 Day 15-7.64 ± 20.36-3.00 ± 31.46
Cycle 16 Day 15-3.33 ± 19.38-3.23 ± 30.52
Cycle 17 Day 15-8.23 ± 17.47-4.76 ± 32.27
Cycle 18 Day 15-9.07 ± 23.65-3.10 ± 27.55
Cycle 19 Day 15-5.38 ± 20.64-5.37 ± 26.16
Cycle 20 Day 15-5.97 ± 18.23-1.09 ± 27.98
Cycle 21 Day 15-6.21 ± 18.25-0.88 ± 28.46
Cycle 22 Day 15-5.80 ± 16.93-0.51 ± 30.76
Cycle 23 Day 15-6.02 ± 14.99-5.17 ± 33.36
Cycle 24 Day 15-4.82 ± 17.291.39 ± 39.90
Cycle 25 Day 15-4.30 ± 16.08-4.17 ± 38.95
Cycle 26 Day 15-6.25 ± 21.88-7.89 ± 31.12
Cycle 27 Day 15-0.83 ± 17.501.28 ± 31.52
Cycle 28 Day 15-4.44 ± 9.89-11.67 ± 35.18
Cycle 29 Day 15-2.38 ± 12.84-10.00 ± 34.43
Cycle 30 Day 154.17 ± 22.61-4.76 ± 29.99
EOT-11.24 ± 26.08-8.00 ± 26.54
SecondaryChange From Baseline in EORTC QLQ-C30: Emotional Functioning

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of emotional functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Emotional Functioning
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 1-1.29 ± 17.922.50 ± 17.94
Cycle 3 Day 150.71 ± 14.501.31 ± 19.12
Cycle 4 Day 15-0.27 ± 17.523.39 ± 20.33
Cycle 5 Day 150.35 ± 17.391.78 ± 18.53
Cycle 6 Day 151.83 ± 17.221.78 ± 19.08
Cycle 7 Day 151.10 ± 19.172.51 ± 19.73
Cycle 8 Day 152.01 ± 17.232.41 ± 19.71
Cycle 9 Day 15-0.64 ± 18.083.53 ± 22.84
Cycle 10 Day 150.28 ± 16.732.10 ± 19.60
Cycle 11 Day 151.31 ± 17.611.41 ± 22.55
Cycle 12 Day 151.25 ± 17.281.33 ± 21.49
Cycle 13 Day 150.81 ± 17.130.51 ± 20.54
Cycle 14 Day 151.26 ± 17.550.16 ± 19.68
Cycle 15 Day 150.61 ± 18.86-0.50 ± 20.34
Cycle 16 Day 15-0.39 ± 17.05-0.90 ± 18.69
Cycle 17 Day 150.21 ± 16.23-3.27 ± 21.06
Cycle 18 Day 15-2.57 ± 16.31-1.19 ± 22.31
Cycle 19 Day 15-2.15 ± 15.16-1.27 ± 22.31
Cycle 20 Day 150.63 ± 14.79-1.81 ± 24.27
Cycle 21 Day 15-0.82 ± 15.571.54 ± 22.99
Cycle 22 Day 151.09 ± 15.483.54 ± 24.30
Cycle 23 Day 15-2.31 ± 15.640.57 ± 28.17
Cycle 24 Day 15-1.10 ± 17.784.17 ± 27.58
Cycle 25 Day 154.84 ± 15.03-7.08 ± 29.90
Cycle 26 Day 153.13 ± 20.97-1.75 ± 31.98
Cycle 27 Day 155.83 ± 17.548.97 ± 16.83
Cycle 28 Day 1512.78 ± 24.774.17 ± 14.30
Cycle 29 Day 155.95 ± 15.8210.00 ± 9.46
Cycle 30 Day 159.03 ± 24.749.52 ± 15.54
EOT-6.37 ± 17.23-3.25 ± 19.85
SecondaryChange From Baseline in EORTC QLQ-C30: Cognitive Functioning

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of cognitive functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Cognitive Functioning
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 1-1.42 ± 16.010.25 ± 19.52
Cycle 3 Day 15-1.21 ± 18.37-1.78 ± 19.45
Cycle 4 Day 15-1.07 ± 18.711.07 ± 17.77
Cycle 5 Day 15-2.51 ± 16.680.20 ± 18.92
Cycle 6 Day 15-2.28 ± 16.800.33 ± 18.37
Cycle 7 Day 15-1.16 ± 17.260.00 ± 18.76
Cycle 8 Day 15-1.88 ± 15.17-1.73 ± 20.39
Cycle 9 Day 15-4.36 ± 17.311.69 ± 18.79
Cycle 10 Day 15-4.68 ± 15.84-1.36 ± 20.09
Cycle 11 Day 15-5.10 ± 16.78-1.41 ± 19.92
Cycle 12 Day 15-4.21 ± 17.150.29 ± 20.53
Cycle 13 Day 15-5.18 ± 16.830.34 ± 20.06
Cycle 14 Day 15-5.72 ± 18.16-1.27 ± 20.76
Cycle 15 Day 15-6.08 ± 19.21-3.50 ± 19.29
Cycle 16 Day 15-4.51 ± 17.70-3.58 ± 19.48
Cycle 17 Day 15-5.27 ± 16.78-4.76 ± 22.34
Cycle 18 Day 15-10.29 ± 20.57-2.38 ± 18.88
Cycle 19 Day 15-8.06 ± 18.29-5.65 ± 17.94
Cycle 20 Day 15-8.81 ± 17.48-3.99 ± 18.32
Cycle 21 Day 15-9.80 ± 17.05-1.75 ± 14.39
Cycle 22 Day 15-6.88 ± 17.42-3.54 ± 15.45
Cycle 23 Day 15-5.56 ± 16.90-5.17 ± 19.47
Cycle 24 Day 15-12.28 ± 19.25-1.39 ± 18.33
Cycle 25 Day 15-13.98 ± 19.77-7.50 ± 23.24
Cycle 26 Day 15-14.58 ± 23.73-6.14 ± 14.92
Cycle 27 Day 15-5.83 ± 17.33-3.85 ± 21.68
Cycle 28 Day 15-11.11 ± 13.61-5.00 ± 11.25
Cycle 29 Day 15-11.90 ± 13.76-5.00 ± 13.72
Cycle 30 Day 15-8.33 ± 16.67-2.38 ± 17.82
EOT-7.87 ± 21.92-1.83 ± 24.03
SecondaryChange From Baseline in EORTC QLQ-C30: Social Functioning

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For functional scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score and a positive change from baseline represents a better level of social functioning. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Social Functioning
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 1-0.80 ± 21.690.08 ± 21.23
Cycle 3 Day 15-0.51 ± 21.732.43 ± 24.17
Cycle 4 Day 15-0.11 ± 20.082.23 ± 24.91
Cycle 5 Day 150.40 ± 22.691.73 ± 24.04
Cycle 6 Day 15-1.03 ± 24.702.22 ± 24.25
Cycle 7 Day 151.27 ± 22.573.85 ± 27.10
Cycle 8 Day 150.38 ± 23.160.74 ± 23.82
Cycle 9 Day 150.90 ± 24.670.28 ± 24.07
Cycle 10 Day 15-1.24 ± 24.92-0.41 ± 23.32
Cycle 11 Day 150.14 ± 21.991.69 ± 25.26
Cycle 12 Day 152.02 ± 22.63-2.06 ± 24.61
Cycle 13 Day 15-1.13 ± 21.551.01 ± 24.49
Cycle 14 Day 15-4.04 ± 22.35-1.43 ± 26.36
Cycle 15 Day 15-1.39 ± 22.38-0.33 ± 27.11
Cycle 16 Day 151.96 ± 19.660.36 ± 22.52
Cycle 17 Day 15-2.95 ± 20.97-0.99 ± 27.67
Cycle 18 Day 15-2.21 ± 25.90-0.71 ± 24.48
Cycle 19 Day 150.27 ± 20.583.11 ± 22.63
Cycle 20 Day 150.94 ± 22.510.72 ± 24.08
Cycle 21 Day 15-1.31 ± 22.813.51 ± 27.44
Cycle 22 Day 150.00 ± 20.494.04 ± 27.65
Cycle 23 Day 15-0.46 ± 20.502.30 ± 29.79
Cycle 24 Day 150.00 ± 20.133.47 ± 27.35
Cycle 25 Day 150.00 ± 20.643.33 ± 27.36
Cycle 26 Day 155.56 ± 20.664.39 ± 25.36
Cycle 27 Day 1511.67 ± 18.817.69 ± 27.74
Cycle 28 Day 1511.11 ± 17.440.00 ± 17.57
Cycle 29 Day 157.14 ± 19.30-6.67 ± 17.92
Cycle 30 Day 159.72 ± 26.077.14 ± 30.21
EOT-8.43 ± 25.14-5.17 ± 30.31
SecondaryChange From Baseline in EORTC QLQ-C30: Fatigue

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Fatigue
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 13.66 ± 20.393.94 ± 19.99
Cycle 3 Day 153.91 ± 21.492.25 ± 20.30
Cycle 4 Day 150.71 ± 19.700.97 ± 20.35
Cycle 5 Day 151.41 ± 19.040.61 ± 20.75
Cycle 6 Day 15-0.91 ± 19.980.52 ± 20.69
Cycle 7 Day 150.77 ± 18.29-0.31 ± 21.79
Cycle 8 Day 150.00 ± 18.351.81 ± 23.71
Cycle 9 Day 152.99 ± 21.510.85 ± 22.65
Cycle 10 Day 151.56 ± 22.051.54 ± 19.83
Cycle 11 Day 152.85 ± 20.962.73 ± 19.10
Cycle 12 Day 151.25 ± 17.220.39 ± 20.57
Cycle 13 Day 150.65 ± 19.111.80 ± 18.83
Cycle 14 Day 152.69 ± 17.821.90 ± 20.00
Cycle 15 Day 152.89 ± 18.681.33 ± 21.73
Cycle 16 Day 153.53 ± 20.302.75 ± 20.83
Cycle 17 Day 152.95 ± 17.222.38 ± 23.40
Cycle 18 Day 155.39 ± 24.241.27 ± 20.94
Cycle 19 Day 156.09 ± 19.374.14 ± 19.67
Cycle 20 Day 155.24 ± 19.320.48 ± 18.88
Cycle 21 Day 153.49 ± 21.14-2.63 ± 20.08
Cycle 22 Day 153.86 ± 19.35-4.71 ± 22.40
Cycle 23 Day 154.32 ± 21.79-3.07 ± 22.40
Cycle 24 Day 150.88 ± 20.40-3.70 ± 24.45
Cycle 25 Day 152.51 ± 21.79-1.11 ± 27.19
Cycle 26 Day 15-0.46 ± 22.58-1.75 ± 24.08
Cycle 27 Day 15-1.67 ± 17.01-8.55 ± 22.75
Cycle 28 Day 150.74 ± 20.77-6.67 ± 16.73
Cycle 29 Day 155.56 ± 18.87-6.67 ± 17.53
Cycle 30 Day 15-2.78 ± 17.81-15.87 ± 23.00
EOT9.99 ± 27.223.56 ± 21.59
SecondaryChange From Baseline in EORTC QLQ-C30: Nausea and Vomiting

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Nausea and Vomiting
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 10.44 ± 13.180.92 ± 12.75
Cycle 3 Day 15-2.22 ± 10.34-0.94 ± 13.69
Cycle 4 Day 15-1.92 ± 11.190.19 ± 14.53
Cycle 5 Day 15-1.20 ± 11.97-0.30 ± 13.75
Cycle 6 Day 15-2.74 ± 11.580.22 ± 11.09
Cycle 7 Day 15-1.62 ± 11.21-0.12 ± 11.95
Cycle 8 Day 15-1.50 ± 11.51-0.74 ± 13.33
Cycle 9 Day 15-0.38 ± 13.84-0.56 ± 11.10
Cycle 10 Day 15-0.41 ± 11.480.27 ± 13.83
Cycle 11 Day 15-1.52 ± 14.91-0.56 ± 12.31
Cycle 12 Day 15-1.09 ± 13.790.15 ± 13.27
Cycle 13 Day 15-1.62 ± 15.22-0.34 ± 17.17
Cycle 14 Day 15-0.84 ± 15.681.43 ± 14.82
Cycle 15 Day 15-1.04 ± 12.75-0.67 ± 12.29
Cycle 16 Day 15-1.18 ± 12.28-0.90 ± 14.19
Cycle 17 Day 151.05 ± 11.110.99 ± 18.54
Cycle 18 Day 15-0.49 ± 9.540.95 ± 13.27
Cycle 19 Day 151.08 ± 15.353.11 ± 18.17
Cycle 20 Day 15-1.57 ± 8.812.17 ± 15.56
Cycle 21 Day 150.00 ± 10.002.63 ± 17.12
Cycle 22 Day 151.45 ± 8.483.03 ± 16.38
Cycle 23 Day 152.78 ± 10.911.72 ± 9.28
Cycle 24 Day 15-0.44 ± 9.082.78 ± 6.34
Cycle 25 Day 15-0.54 ± 11.770.83 ± 6.57
Cycle 26 Day 150.00 ± 12.044.39 ± 13.43
Cycle 27 Day 15-0.83 ± 12.651.28 ± 8.23
Cycle 28 Day 15-2.22 ± 10.671.67 ± 5.27
Cycle 29 Day 150.00 ± 16.011.67 ± 5.27
Cycle 30 Day 15-2.78 ± 11.962.38 ± 6.30
EOT1.69 ± 20.26-1.33 ± 16.70
SecondaryChange From Baseline in EORTC QLQ-C30: Pain

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom scales: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptoms and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Pain
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 1-3.63 ± 26.70-5.50 ± 24.51
Cycle 3 Day 15-6.36 ± 22.50-8.80 ± 25.68
Cycle 4 Day 15-7.48 ± 19.70-6.59 ± 25.08
Cycle 5 Day 15-6.02 ± 21.88-8.64 ± 26.01
Cycle 6 Day 15-6.96 ± 21.51-8.67 ± 26.31
Cycle 7 Day 15-6.83 ± 22.42-9.21 ± 28.44
Cycle 8 Day 15-7.02 ± 19.59-4.32 ± 25.35
Cycle 9 Day 15-8.46 ± 23.04-4.66 ± 25.49
Cycle 10 Day 15-4.55 ± 22.05-6.64 ± 26.11
Cycle 11 Day 15-4.82 ± 21.88-5.51 ± 25.04
Cycle 12 Day 15-4.67 ± 21.81-5.31 ± 24.63
Cycle 13 Day 15-3.07 ± 21.23-4.21 ± 25.90
Cycle 14 Day 15-4.21 ± 22.25-2.86 ± 25.99
Cycle 15 Day 15-2.08 ± 21.39-3.83 ± 25.50
Cycle 16 Day 15-3.53 ± 22.87-3.76 ± 23.71
Cycle 17 Day 15-0.84 ± 21.00-0.99 ± 26.68
Cycle 18 Day 15-0.98 ± 17.96-2.62 ± 25.00
Cycle 19 Day 15-1.08 ± 20.22-2.26 ± 26.16
Cycle 20 Day 15-1.89 ± 18.68-6.52 ± 31.91
Cycle 21 Day 150.65 ± 18.84-10.09 ± 30.64
Cycle 22 Day 15-3.62 ± 18.23-4.55 ± 33.92
Cycle 23 Day 153.24 ± 17.28-4.60 ± 35.88
Cycle 24 Day 151.32 ± 20.64-6.94 ± 34.37
Cycle 25 Day 150.54 ± 17.99-5.83 ± 30.72
Cycle 26 Day 152.78 ± 18.82-11.40 ± 34.27
Cycle 27 Day 15-0.83 ± 19.85-2.56 ± 31.80
Cycle 28 Day 154.44 ± 20.38-11.67 ± 28.38
Cycle 29 Day 159.52 ± 12.60-11.67 ± 28.38
Cycle 30 Day 15-8.33 ± 25.13-14.29 ± 20.25
EOT3.56 ± 31.534.50 ± 23.31
SecondaryChange From Baseline in EORTC QLQ-C30: Dyspnea

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Dyspnea
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 15.14 ± 22.413.67 ± 21.60
Cycle 3 Day 156.87 ± 25.101.12 ± 22.10
Cycle 4 Day 154.91 ± 22.971.74 ± 20.16
Cycle 5 Day 153.01 ± 24.843.25 ± 21.91
Cycle 6 Day 154.57 ± 23.692.67 ± 19.89
Cycle 7 Day 154.86 ± 23.971.17 ± 20.33
Cycle 8 Day 156.77 ± 25.545.43 ± 22.75
Cycle 9 Day 158.21 ± 25.272.54 ± 21.86
Cycle 10 Day 154.68 ± 21.223.25 ± 22.75
Cycle 11 Day 156.34 ± 24.843.11 ± 19.48
Cycle 12 Day 155.61 ± 26.506.78 ± 23.21
Cycle 13 Day 157.44 ± 24.675.72 ± 22.36
Cycle 14 Day 155.72 ± 23.356.98 ± 22.02
Cycle 15 Day 158.33 ± 23.696.67 ± 23.69
Cycle 16 Day 155.49 ± 23.485.38 ± 21.59
Cycle 17 Day 158.44 ± 20.307.14 ± 20.09
Cycle 18 Day 159.80 ± 25.143.81 ± 20.88
Cycle 19 Day 158.06 ± 23.1311.86 ± 25.34
Cycle 20 Day 156.92 ± 21.046.52 ± 18.08
Cycle 21 Day 1511.11 ± 21.779.65 ± 20.37
Cycle 22 Day 157.97 ± 18.845.05 ± 20.62
Cycle 23 Day 1511.11 ± 25.204.60 ± 14.70
Cycle 24 Day 1510.53 ± 28.062.78 ± 19.45
Cycle 25 Day 157.53 ± 16.586.67 ± 17.44
Cycle 26 Day 159.72 ± 18.335.26 ± 20.07
Cycle 27 Day 1510.00 ± 19.045.13 ± 18.49
Cycle 28 Day 1511.11 ± 24.123.33 ± 18.92
Cycle 29 Day 157.14 ± 19.3010.00 ± 16.10
Cycle 30 Day 152.78 ± 26.43-4.76 ± 12.60
EOT10.11 ± 26.786.00 ± 21.39
SecondaryChange From Baseline in EORTC QLQ-C30: Insomnia

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Insomnia
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 10.71 ± 27.78-3.67 ± 27.31
Cycle 3 Day 15-4.24 ± 26.84-4.68 ± 29.16
Cycle 4 Day 15-5.56 ± 25.63-7.95 ± 30.08
Cycle 5 Day 15-4.82 ± 29.19-2.85 ± 29.86
Cycle 6 Day 15-3.65 ± 27.72-3.78 ± 28.78
Cycle 7 Day 15-1.85 ± 26.38-3.26 ± 29.95
Cycle 8 Day 15-2.51 ± 27.71-5.19 ± 26.66
Cycle 9 Day 15-2.31 ± 27.28-7.06 ± 30.77
Cycle 10 Day 15-0.55 ± 24.34-4.07 ± 30.35
Cycle 11 Day 15-1.10 ± 27.53-1.13 ± 29.54
Cycle 12 Day 15-2.18 ± 26.41-7.37 ± 29.46
Cycle 13 Day 15-3.88 ± 27.34-5.39 ± 26.81
Cycle 14 Day 150.00 ± 29.74-1.90 ± 27.28
Cycle 15 Day 152.43 ± 27.46-4.33 ± 24.00
Cycle 16 Day 15-1.57 ± 26.18-4.66 ± 25.82
Cycle 17 Day 15-2.53 ± 24.33-3.97 ± 28.06
Cycle 18 Day 150.98 ± 26.37-5.24 ± 28.17
Cycle 19 Day 153.23 ± 26.80-2.82 ± 27.88
Cycle 20 Day 15-3.14 ± 26.36-1.45 ± 22.17
Cycle 21 Day 15-0.65 ± 24.49-4.39 ± 22.15
Cycle 22 Day 150.00 ± 25.34-3.03 ± 25.50
Cycle 23 Day 15-0.93 ± 27.01-2.30 ± 32.04
Cycle 24 Day 15-5.26 ± 27.43-2.78 ± 27.66
Cycle 25 Day 15-4.30 ± 28.210.00 ± 26.49
Cycle 26 Day 15-1.39 ± 33.30-3.51 ± 15.29
Cycle 27 Day 15-6.67 ± 23.205.13 ± 18.49
Cycle 28 Day 150.00 ± 21.823.33 ± 18.92
Cycle 29 Day 15-4.76 ± 25.683.33 ± 24.60
Cycle 30 Day 15-11.11 ± 16.419.52 ± 16.27
EOT-1.50 ± 31.35-5.33 ± 31.33
SecondaryChange From Baseline in EORTC QLQ-C30: Appetite Loss

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Appetite Loss
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 1-0.35 ± 22.601.50 ± 20.68
Cycle 3 Day 15-4.44 ± 18.60-2.43 ± 23.51
Cycle 4 Day 15-4.06 ± 21.86-0.39 ± 22.51
Cycle 5 Day 15-3.41 ± 20.64-0.81 ± 23.92
Cycle 6 Day 15-6.39 ± 22.60-3.33 ± 22.77
Cycle 7 Day 15-5.79 ± 20.23-2.33 ± 21.54
Cycle 8 Day 15-4.76 ± 19.74-1.73 ± 23.15
Cycle 9 Day 15-2.82 ± 27.54-0.56 ± 20.43
Cycle 10 Day 15-3.86 ± 19.34-0.27 ± 20.69
Cycle 11 Day 15-1.10 ± 23.54-1.98 ± 23.59
Cycle 12 Day 15-1.87 ± 26.24-2.06 ± 21.95
Cycle 13 Day 15-1.62 ± 20.55-3.03 ± 22.88
Cycle 14 Day 15-2.69 ± 26.37-0.32 ± 22.41
Cycle 15 Day 15-1.74 ± 21.83-0.33 ± 27.01
Cycle 16 Day 15-6.67 ± 24.01-1.79 ± 23.76
Cycle 17 Day 15-4.64 ± 19.05-0.40 ± 22.25
Cycle 18 Day 15-2.94 ± 23.560.00 ± 19.66
Cycle 19 Day 15-3.23 ± 23.152.82 ± 20.80
Cycle 20 Day 15-3.77 ± 23.262.90 ± 23.12
Cycle 21 Day 15-3.92 ± 21.75-1.75 ± 17.24
Cycle 22 Day 15-2.17 ± 24.75-2.02 ± 14.29
Cycle 23 Day 15-4.63 ± 24.110.00 ± 25.20
Cycle 24 Day 15-2.63 ± 28.35-1.39 ± 23.01
Cycle 25 Day 15-2.15 ± 27.131.67 ± 22.88
Cycle 26 Day 15-2.78 ± 30.950.00 ± 11.11
Cycle 27 Day 15-3.33 ± 32.26-7.69 ± 14.62
Cycle 28 Day 15-11.11 ± 20.57-10.00 ± 16.10
Cycle 29 Day 15-11.90 ± 21.11-10.00 ± 16.10
Cycle 30 Day 15-13.89 ± 22.29-9.52 ± 16.27
EOT7.49 ± 35.093.67 ± 29.17
SecondaryChange From Baseline in EORTC QLQ-C30: Constipation

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Constipation
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 14.79 ± 25.703.83 ± 27.59
Cycle 3 Day 155.86 ± 26.799.74 ± 28.87
Cycle 4 Day 156.20 ± 24.488.14 ± 28.58
Cycle 5 Day 157.43 ± 28.045.69 ± 28.98
Cycle 6 Day 157.08 ± 23.566.00 ± 28.92
Cycle 7 Day 157.18 ± 26.204.43 ± 30.19
Cycle 8 Day 157.02 ± 26.612.47 ± 27.21
Cycle 9 Day 155.13 ± 24.364.80 ± 23.58
Cycle 10 Day 153.58 ± 22.697.32 ± 25.08
Cycle 11 Day 154.13 ± 23.405.08 ± 27.78
Cycle 12 Day 152.80 ± 21.046.49 ± 29.16
Cycle 13 Day 156.47 ± 23.377.07 ± 27.47
Cycle 14 Day 155.05 ± 23.027.62 ± 25.84
Cycle 15 Day 154.86 ± 25.583.33 ± 25.73
Cycle 16 Day 152.75 ± 21.955.73 ± 29.33
Cycle 17 Day 154.22 ± 22.8811.51 ± 29.50
Cycle 18 Day 156.86 ± 26.116.19 ± 27.97
Cycle 19 Day 154.30 ± 25.245.65 ± 27.09
Cycle 20 Day 152.52 ± 23.435.80 ± 25.63
Cycle 21 Day 157.84 ± 20.644.39 ± 29.17
Cycle 22 Day 157.97 ± 21.305.05 ± 33.46
Cycle 23 Day 155.56 ± 16.900.00 ± 25.20
Cycle 24 Day 158.77 ± 22.842.78 ± 30.95
Cycle 25 Day 157.53 ± 22.295.00 ± 34.67
Cycle 26 Day 154.17 ± 20.41-1.75 ± 28.27
Cycle 27 Day 15-1.67 ± 20.167.69 ± 33.76
Cycle 28 Day 15-4.44 ± 17.210.00 ± 27.22
Cycle 29 Day 154.76 ± 25.680.00 ± 22.22
Cycle 30 Day 15-2.78 ± 17.16-4.76 ± 23.00
EOT3.00 ± 30.00-0.33 ± 24.84
SecondaryChange From Baseline in EORTC QLQ-C30: Diarrhea

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of symptomatology. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Diarrhea
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 1-3.19 ± 21.84-3.33 ± 23.86
Cycle 3 Day 15-4.65 ± 24.11-5.62 ± 23.36
Cycle 4 Day 15-4.70 ± 19.84-2.13 ± 24.75
Cycle 5 Day 15-4.22 ± 20.49-3.46 ± 23.53
Cycle 6 Day 15-0.91 ± 21.06-3.11 ± 23.91
Cycle 7 Day 15-2.78 ± 20.67-3.96 ± 25.79
Cycle 8 Day 15-5.26 ± 20.86-3.70 ± 25.32
Cycle 9 Day 15-4.36 ± 24.69-3.67 ± 26.07
Cycle 10 Day 15-2.48 ± 26.23-0.81 ± 25.77
Cycle 11 Day 15-3.86 ± 22.85-4.52 ± 23.84
Cycle 12 Day 15-4.05 ± 24.96-4.13 ± 24.04
Cycle 13 Day 15-0.65 ± 24.24-2.69 ± 24.60
Cycle 14 Day 15-0.67 ± 22.33-3.17 ± 26.36
Cycle 15 Day 15-2.78 ± 24.02-1.33 ± 21.15
Cycle 16 Day 15-3.14 ± 25.52-1.43 ± 23.01
Cycle 17 Day 15-4.64 ± 20.490.00 ± 25.87
Cycle 18 Day 15-0.98 ± 25.08-5.71 ± 20.44
Cycle 19 Day 15-5.38 ± 24.29-2.26 ± 25.42
Cycle 20 Day 15-3.14 ± 27.94-2.17 ± 19.12
Cycle 21 Day 15-5.88 ± 21.81-0.88 ± 21.21
Cycle 22 Day 15-5.80 ± 24.65-3.03 ± 19.30
Cycle 23 Day 15-4.63 ± 22.75-6.90 ± 18.64
Cycle 24 Day 15-5.26 ± 27.43-1.39 ± 18.33
Cycle 25 Day 15-1.08 ± 21.92-8.33 ± 14.81
Cycle 26 Day 15-1.39 ± 25.02-7.02 ± 21.02
Cycle 27 Day 15-6.67 ± 20.52-5.13 ± 12.52
Cycle 28 Day 15-11.11 ± 24.12-10.00 ± 16.10
Cycle 29 Day 15-14.29 ± 21.54-3.33 ± 18.92
Cycle 30 Day 15-11.11 ± 29.59-4.76 ± 12.60
EOT-1.50 ± 22.42-4.33 ± 24.92
SecondaryChange From Baseline in EORTC QLQ-C30: Financial Difficulties

EORTC QLQ-C30 is a cancer specific 30-item instrument that provides a comprehensive assessment of the principal health related QoL dimensions: GHS/QoL (2 items), functional scales (physical \[5 items\], role \[2 items\], emotional \[4 items\], cognitive \[2 items\], social \[2 items\]), symptom scales (fatigue \[3 items\], nausea \& vomiting \[2 items\], pain \[2 items\]) and symptom items- 1 item each (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). For symptom items: questions were rated on a 4-point scale (1: not at all to 4: very much). All of the scales and single-item measures range in score from 0 to 100; mean is presented here. A higher score for symptom items and a positive change from baseline represents a higher level of financial difficulties. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-C30: Financial Difficulties
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 1-2.66 ± 21.50-5.00 ± 24.50
Cycle 3 Day 15-2.63 ± 22.69-4.68 ± 28.51
Cycle 4 Day 15-1.50 ± 22.51-3.68 ± 28.03
Cycle 5 Day 15-3.41 ± 22.51-4.27 ± 30.03
Cycle 6 Day 15-0.68 ± 21.25-3.78 ± 31.02
Cycle 7 Day 15-1.62 ± 23.10-4.43 ± 31.71
Cycle 8 Day 15-3.76 ± 21.58-3.46 ± 32.65
Cycle 9 Day 150.77 ± 24.72-6.21 ± 30.18
Cycle 10 Day 15-2.75 ± 24.57-4.61 ± 29.36
Cycle 11 Day 15-1.93 ± 21.21-5.93 ± 29.12
Cycle 12 Day 15-2.49 ± 24.95-3.54 ± 29.33
Cycle 13 Day 15-2.91 ± 23.85-3.03 ± 30.15
Cycle 14 Day 15-1.01 ± 24.49-3.17 ± 27.16
Cycle 15 Day 151.04 ± 27.12-2.33 ± 28.92
Cycle 16 Day 15-2.35 ± 25.09-0.72 ± 27.35
Cycle 17 Day 150.84 ± 21.33-4.37 ± 28.71
Cycle 18 Day 15-1.96 ± 25.03-3.81 ± 28.11
Cycle 19 Day 15-2.69 ± 24.37-5.08 ± 30.83
Cycle 20 Day 15-5.03 ± 22.07-3.62 ± 33.87
Cycle 21 Day 15-6.54 ± 23.11-7.02 ± 30.17
Cycle 22 Day 15-8.70 ± 21.59-7.07 ± 30.91
Cycle 23 Day 15-5.56 ± 23.23-5.75 ± 29.64
Cycle 24 Day 15-5.26 ± 27.43-9.72 ± 28.62
Cycle 25 Day 15-8.60 ± 25.77-5.00 ± 39.40
Cycle 26 Day 15-13.89 ± 21.80-3.51 ± 36.67
Cycle 27 Day 15-16.67 ± 25.36-10.26 ± 43.85
Cycle 28 Day 15-15.56 ± 24.77-3.33 ± 42.89
Cycle 29 Day 15-14.29 ± 25.20-3.33 ± 39.91
Cycle 30 Day 15-11.11 ± 21.714.76 ± 23.00
EOT5.24 ± 23.52-1.33 ± 33.81
SecondaryChange From Baseline in EORTC QLQ-Myeloma Module (MY20): Disease Symptoms

The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for disease symptoms and a positive change from baseline represents more symptoms, worse QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-Myeloma Module (MY20): Disease Symptoms
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 1-4.59 ± 15.80-5.38 ± 15.58
Cycle 3 Day 15-5.28 ± 15.74-5.91 ± 17.75
Cycle 4 Day 15-5.08 ± 13.89-6.59 ± 16.90
Cycle 5 Day 15-5.52 ± 16.55-8.63 ± 18.18
Cycle 6 Day 15-6.66 ± 15.88-8.56 ± 19.26
Cycle 7 Day 15-6.33 ± 15.79-8.51 ± 17.64
Cycle 8 Day 15-4.72 ± 14.22-7.10 ± 19.56
Cycle 9 Day 15-6.33 ± 16.43-7.52 ± 20.71
Cycle 10 Day 15-4.87 ± 15.72-7.21 ± 18.25
Cycle 11 Day 15-5.10 ± 14.48-7.57 ± 19.46
Cycle 12 Day 15-4.83 ± 16.33-7.99 ± 18.92
Cycle 13 Day 15-4.48 ± 16.54-5.44 ± 17.20
Cycle 14 Day 15-5.16 ± 14.90-6.36 ± 17.25
Cycle 15 Day 15-3.82 ± 16.49-5.67 ± 17.99
Cycle 16 Day 15-5.82 ± 16.26-5.25 ± 17.65
Cycle 17 Day 15-2.18 ± 14.22-4.02 ± 19.02
Cycle 18 Day 15-0.66 ± 13.90-6.28 ± 17.95
Cycle 19 Day 15-1.61 ± 12.50-6.13 ± 18.34
Cycle 20 Day 15-3.25 ± 14.51-10.99 ± 18.93
Cycle 21 Day 15-1.20 ± 13.58-8.92 ± 19.23
Cycle 22 Day 15-2.54 ± 14.75-6.94 ± 22.04
Cycle 23 Day 15-0.31 ± 11.26-7.14 ± 20.50
Cycle 24 Day 15-1.61 ± 13.97-8.70 ± 20.30
Cycle 25 Day 15-0.72 ± 16.34-9.72 ± 23.07
Cycle 26 Day 15-2.31 ± 15.53-9.57 ± 19.41
Cycle 27 Day 15-2.22 ± 16.16-10.68 ± 26.30
Cycle 28 Day 150.00 ± 13.61-13.58 ± 24.07
Cycle 29 Day 150.40 ± 6.34-15.00 ± 25.40
Cycle 30 Day 15-4.17 ± 15.19-15.08 ± 17.19
EOT2.40 ± 22.862.92 ± 19.77
SecondaryChange From Baseline in EORTC QLQ-MY20: Side Effects of Treatment

The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for side effects of treatment and a positive change from baseline represents more side effects, worse QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-MY20: Side Effects of Treatment
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 11.94 ± 11.340.23 ± 12.22
Cycle 3 Day 151.68 ± 11.260.45 ± 13.29
Cycle 4 Day 152.23 ± 12.340.04 ± 14.86
Cycle 5 Day 152.51 ± 12.181.75 ± 15.06
Cycle 6 Day 151.18 ± 13.17-0.76 ± 13.28
Cycle 7 Day 151.47 ± 13.01-0.42 ± 15.12
Cycle 8 Day 150.97 ± 12.860.34 ± 14.70
Cycle 9 Day 152.03 ± 13.58-0.05 ± 14.70
Cycle 10 Day 153.64 ± 13.041.00 ± 14.46
Cycle 11 Day 152.27 ± 13.491.03 ± 14.77
Cycle 12 Day 152.08 ± 12.780.49 ± 15.06
Cycle 13 Day 152.41 ± 13.790.31 ± 13.51
Cycle 14 Day 154.18 ± 13.641.24 ± 15.14
Cycle 15 Day 153.50 ± 12.130.71 ± 14.03
Cycle 16 Day 153.72 ± 13.101.79 ± 14.73
Cycle 17 Day 153.85 ± 10.712.06 ± 15.14
Cycle 18 Day 153.99 ± 13.150.37 ± 13.34
Cycle 19 Day 154.93 ± 13.540.94 ± 12.65
Cycle 20 Day 153.87 ± 12.740.84 ± 16.03
Cycle 21 Day 153.22 ± 12.70-0.99 ± 15.09
Cycle 22 Day 152.10 ± 11.26-0.88 ± 18.18
Cycle 23 Day 151.10 ± 11.83-1.32 ± 17.03
Cycle 24 Day 150.56 ± 11.39-3.17 ± 16.57
Cycle 25 Day 153.24 ± 13.69-1.30 ± 19.03
Cycle 26 Day 151.88 ± 15.40-2.10 ± 15.04
Cycle 27 Day 150.98 ± 14.42-3.33 ± 18.51
Cycle 28 Day 15-0.27 ± 16.41-2.18 ± 14.63
Cycle 29 Day 151.75 ± 13.47-3.78 ± 13.95
Cycle 30 Day 15-2.69 ± 20.07-4.02 ± 12.18
EOT2.95 ± 13.990.69 ± 13.93
SecondaryChange From Baseline in EORTC QLQ-MY20: Future Perspective

The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for future perspectives and a positive change from baseline represents better outcomes, better QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-MY20: Future Perspective
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 12.76 ± 19.185.47 ± 19.91
Cycle 3 Day 153.96 ± 20.686.72 ± 22.14
Cycle 4 Day 155.41 ± 22.339.73 ± 24.08
Cycle 5 Day 154.31 ± 22.818.70 ± 22.38
Cycle 6 Day 154.57 ± 21.718.81 ± 23.75
Cycle 7 Day 155.28 ± 21.589.48 ± 24.03
Cycle 8 Day 156.02 ± 19.418.27 ± 23.44
Cycle 9 Day 154.48 ± 23.2210.15 ± 24.01
Cycle 10 Day 154.41 ± 18.678.17 ± 23.16
Cycle 11 Day 154.87 ± 17.397.38 ± 25.33
Cycle 12 Day 155.30 ± 17.296.25 ± 25.43
Cycle 13 Day 155.07 ± 18.986.12 ± 25.03
Cycle 14 Day 154.71 ± 21.485.24 ± 24.72
Cycle 15 Day 153.59 ± 20.994.83 ± 26.76
Cycle 16 Day 157.06 ± 21.547.37 ± 26.32
Cycle 17 Day 153.94 ± 18.233.08 ± 23.43
Cycle 18 Day 155.80 ± 22.594.99 ± 25.32
Cycle 19 Day 153.94 ± 18.560.77 ± 26.40
Cycle 20 Day 156.50 ± 16.94-0.25 ± 27.78
Cycle 21 Day 156.54 ± 17.384.09 ± 25.89
Cycle 22 Day 157.73 ± 17.191.04 ± 25.30
Cycle 23 Day 154.94 ± 17.100.79 ± 23.80
Cycle 24 Day 159.65 ± 22.256.28 ± 26.34
Cycle 25 Day 157.89 ± 22.991.67 ± 28.68
Cycle 26 Day 158.33 ± 23.68-3.09 ± 29.96
Cycle 27 Day 158.33 ± 23.3311.97 ± 28.50
Cycle 28 Day 1514.07 ± 28.323.70 ± 23.57
Cycle 29 Day 157.94 ± 21.09-1.11 ± 21.24
Cycle 30 Day 1512.04 ± 28.216.35 ± 15.53
EOT-3.41 ± 22.56-1.91 ± 24.90
SecondaryChange From Baseline in EORTC QLQ-MY20: Body Image

The EORTC QLQ-MY20 was used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to the treatment or the disease which impacts health related QoL in participants with MM. It contains 20 items, 4 independent subscales covering 2 functional domains: symptom scales which include disease symptoms (6 items) and side-effects of treatment (10 items) and function scale which include future perspective (3 items) and body image (1 item). Scores for each subscale are based on the 4-point Likert scale ranging from (1: not at all to 4: very much) and transformed from raw scores to linear scales ranging from 0 to 100; mean is presented here. A higher score for body image and a positive change from baseline represents better outcomes, better QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 30 Day 15 and EOT visit (up to DCO date: 29-Aug-2025) (30 days after last drug administration or before further anti myeloma therapy initiation,whichever occurred first,up to approximately 38 months)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-MY20: Body Image
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 13.24 ± 25.332.59 ± 26.55
Cycle 3 Day 151.88 ± 26.501.55 ± 23.59
Cycle 4 Day 150.88 ± 24.254.76 ± 25.24
Cycle 5 Day 15-0.61 ± 27.172.90 ± 24.83
Cycle 6 Day 15-0.91 ± 25.655.78 ± 26.40
Cycle 7 Day 15-1.17 ± 28.094.20 ± 25.60
Cycle 8 Day 15-1.00 ± 25.933.76 ± 22.72
Cycle 9 Day 151.55 ± 25.305.17 ± 24.32
Cycle 10 Day 15-0.55 ± 25.453.58 ± 26.11
Cycle 11 Day 15-3.58 ± 23.881.72 ± 23.61
Cycle 12 Day 15-1.25 ± 24.200.89 ± 23.87
Cycle 13 Day 15-3.24 ± 28.212.72 ± 25.18
Cycle 14 Day 15-3.70 ± 29.311.92 ± 24.94
Cycle 15 Day 15-4.17 ± 30.304.38 ± 23.16
Cycle 16 Day 15-1.57 ± 29.050.00 ± 25.20
Cycle 17 Day 15-2.53 ± 26.57-2.41 ± 24.85
Cycle 18 Day 15-1.00 ± 28.411.45 ± 25.84
Cycle 19 Day 15-2.15 ± 27.57-1.15 ± 26.47
Cycle 20 Day 152.52 ± 28.38-3.70 ± 27.73
Cycle 21 Day 15-3.27 ± 34.801.75 ± 21.85
Cycle 22 Day 151.45 ± 29.785.21 ± 24.11
Cycle 23 Day 15-1.85 ± 29.761.19 ± 23.10
Cycle 24 Day 152.63 ± 36.667.25 ± 22.38
Cycle 25 Day 151.08 ± 34.943.33 ± 18.42
Cycle 26 Day 156.94 ± 36.759.26 ± 25.06
Cycle 27 Day 1513.33 ± 34.887.69 ± 19.97
Cycle 28 Day 156.67 ± 28.730.00 ± 16.67
Cycle 29 Day 154.76 ± 36.653.33 ± 18.92
Cycle 30 Day 1513.89 ± 30.019.52 ± 16.27
EOT-4.92 ± 27.930.67 ± 27.35
SecondaryChange From Baseline in European Quality of Life Group Measure With 5 Dimensions and 5 Levels Per Dimension (EQ-5D-5L): Visual Analogue Scale (VAS)

The EQ-5D-5L is a standardized measure of health status that provides a simple, generic measure of health utility, and consists of 2 sections: descriptive and a VAS. The descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The VAS records the respondent's self-rated health on a 20-cm vertical scale ranging from 0: the worst health you can imagine to 100: the best health you can imagine. Change from baseline in VAS is reported here. A higher score in VAS and positive change from baseline represents a better level of QoL. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.

Time frame:
Baseline (Cycle 1 Day 1) and Cycle 2 Day 1, Cycles 3 to 21 Day 15 and EOT visit (up to PCD: 06-Nov-2024) (30 days after last drug administration or before further anti myeloma therapy initiation, whichever occurred first, up to approximately 28 months)
Reported as:
Mean · score on a scale
Change From Baseline in European Quality of Life Group Measure With 5 Dimensions and 5 Levels Per Dimension (EQ-5D-5L): Visual Analogue Scale (VAS)
score on a scaleIsa-IV + PdIsa-SC + Pd
Cycle 2 Day 10.99 ± 17.62-0.39 ± 14.58
Cycle 3 Day 15-0.52 ± 17.35-0.10 ± 16.28
Cycle 4 Day 150.75 ± 18.66-0.24 ± 19.36
Cycle 5 Day 150.09 ± 17.781.03 ± 19.20
Cycle 6 Day 150.50 ± 19.542.39 ± 18.17
Cycle 7 Day 15-1.55 ± 20.693.02 ± 18.01
Cycle 8 Day 150.12 ± 17.97-0.14 ± 18.03
Cycle 9 Day 150.87 ± 19.390.62 ± 16.07
Cycle 10 Day 152.65 ± 15.862.38 ± 15.85
Cycle 11 Day 15-0.51 ± 20.30-1.66 ± 17.53
Cycle 12 Day 151.97 ± 20.67-0.51 ± 17.55
Cycle 13 Day 152.83 ± 18.713.41 ± 15.74
Cycle 14 Day 151.58 ± 18.62-0.83 ± 17.36
Cycle 15 Day 152.41 ± 20.90-1.69 ± 17.75
Cycle 16 Day 152.38 ± 20.480.72 ± 19.44
Cycle 17 Day 152.90 ± 18.33-0.13 ± 17.38
Cycle 18 Day 153.45 ± 15.700.53 ± 23.17
Cycle 19 Day 15-0.05 ± 18.17-6.00 ± 15.16
Cycle 20 Day 15-2.14 ± 12.24-2.92 ± 21.34
Cycle 21 Day 15-5.20 ± 24.931.88 ± 9.19
EOT visit-4.25 ± 21.94-5.17 ± 17.11
SecondaryORR Based on at Least 1 Chromosomal Abnormality

BM aspirate was collected for fluorescent in situ hybridization for analysis of del\[17p\], t\[4;14\], t\[14;16\]) and 1q21+. ORR was also evaluated based on IRC assessment by disease characteristics. ORR for participants with at least 1 chromosomal abnormality i.e. \[del(17p)\] or \[1q21+ and t(4;14) or t(14;16)\] is presented. Percentages are rounded off to the tenth decimal place.

Time frame:
From first dose of study medication administration (Day 1) up to DCO date (29-Aug-2025), approximately 38 months
Reported as:
Number · percentage of participants
ORR Based on at Least 1 Chromosomal Abnormality
percentage of participantsIsa-IV + PdIsa-SC + Pd
ORR Based on at Least 1 Chromosomal Abnormality62.362.5

Adverse events

Collected over Adverse events and deaths were collected from first dose of study medication administration (Day 1) up to 30 days after the last dose of study medication, approximately 38 months. Partial results are presented up to DCO date of 29-Aug-2025.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Isa-IV + Pd73/268 (27.2%)152/264 (57.6%)248/264 (93.9%)
Isa-SC + Pd77/263 (29.3%)160/263 (60.8%)242/263 (92%)
Most frequent serious events
Showing 10 of 226
Most frequent serious events
EventIsa-IV + PdIsa-SC + Pd
PneumoniaInfections and infestations48/26454/263
Covid-19Infections and infestations7/26411/263
Febrile NeutropeniaBlood and lymphatic system disorders5/2649/263
Platelet Count DecreasedInvestigations9/2644/263
Acute Kidney InjuryRenal and urinary disorders2/2648/263
Covid-19 PneumoniaInfections and infestations6/2647/263
AnaemiaBlood and lymphatic system disorders4/2646/263
InfluenzaInfections and infestations6/2644/263
Pneumonia InfluenzalInfections and infestations6/2645/263
Disease ProgressionGeneral disorders6/2644/263
Most frequent other events
Showing 10 of 38
Most frequent other events
EventIsa-IV + PdIsa-SC + Pd
NeutropeniaBlood and lymphatic system disorders88/26493/263
Upper Respiratory Tract InfectionInfections and infestations76/26474/263
DiarrhoeaGastrointestinal disorders67/26460/263
Infusion Related ReactionInjury, poisoning and procedural complications63/2646/263
FatigueGeneral disorders43/26457/263
Neutrophil Count DecreasedInvestigations41/26448/263
InsomniaPsychiatric disorders42/26446/263
ConstipationGastrointestinal disorders39/26439/263
Oedema PeripheralGeneral disorders38/26433/263
Covid-19Infections and infestations36/26432/263

Baseline characteristics

Baseline characteristics were assessed for all randomized population.

Age, Continuous
Age, Continuous(years)Isa-IV + PdIsa-SC + PdTotal
Mean64.7 ± 9.765.7 ± 9.465.2 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Isa-IV + PdIsa-SC + PdTotal
Female112126238
Male156137293
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Isa-IV + PdIsa-SC + PdTotal
American Indian or Alaska Native101
Asian5853111
Native Hawaiian or Other Pacific Islander011
Black or African American14822
White184184368
More than one race033
Unknown or Not Reported111425
08

Study locations

128 sites
  • Rocky Mountain Cancer Centers - Aurora- Site Number : 8400021
    Aurora, Colorado 80012, United States
  • Mayo Clinic in Florida- Site Number : 8400008
    Jacksonville, Florida 32224, United States
  • Boca Raton Clinical Research Associates- Site Number : 8400030
    Plantation, Florida 33322, United States
  • Hattiesburg Clinic- Site Number : 8400006
    Hattiesburg, Mississippi 39401, United States
  • Atlantic Health System- Site Number : 8400005
    Morristown, New Jersey 07962, United States
  • New York Oncology Hematology - Albany Cancer Center- Site Number : 8400017
    Albany, New York 12206, United States
  • Novant Health Neurology & Sleep- Site Number : 8400014
    Charlotte, North Carolina 28207, United States
  • Gabrail Cancer Center- Site Number : 8400027
    Canton, Ohio 44718, United States
  • Oncology Hematology Care - Fairfield- Site Number : 8400016
    Fairfield, Ohio 45014, United States
  • Spartanburg Regional Medical Center- Site Number : 8400002
    Spartanburg, South Carolina 29303, United States
  • University of Texas - Southwestern Medical Center- Site Number : 8400024
    Dallas, Texas 75390, United States
  • Texas Oncology - San Antonio Medical Center - Research Drive- Site Number : 8400020
    San Antonio, Texas 78240, United States
  • Veterans Affairs Medical Center - Salt Lake City- Site Number : 8400011
    Salt Lake City, Utah 84108, United States
  • Investigational Site Number : 0320006
    La Plata, Buenos Aires 1900, Argentina
  • Investigational Site Number : 0320008
    Buenos Aires, 1180, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1181, Argentina
  • Investigational Site Number : 0320007
    Buenos Aires, 1280, Argentina
  • Investigational Site Number : 0320003
    Buenos Aires, 1417, Argentina
  • Investigational Site Number : 0320004
    Buenos Aires, 1426, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1430, Argentina
  • Investigational Site Number : 0320005
    Buenos Aires, 1431, Argentina
  • Investigational Site Number : 0320010
    Córdoba, 5000, Argentina
  • Investigational Site Number : 0320009
    Mendoza, 5501, Argentina
  • Investigational Site Number : 0360007
    Liverpool, New South Wales 2170, Australia
  • Investigational Site Number : 0360004
    Waratah, New South Wales 2298, Australia
  • Investigational Site Number : 0360003
    Wollongong, New South Wales 2500, Australia
  • Investigational Site Number : 0360008
    Adelaide, South Australia 5000, Australia
  • Investigational Site Number : 0360006
    Melbourne, Victoria 3004, Australia
  • Investigational Site Number : 0360009
    Melbourne, Victoria 3065, Australia
  • Investigational Site Number : 0360001
    Richmond, Victoria 3121, Australia
  • Núcleo de Oncologia e Hematologia do Ceará- Site Number : 0760006
    Fortaleza, Ceará 60115-280, Brazil
  • MultiHemo - Recife - Rua Padre Carapuceiro- Site Number : 0760007
    Recife, Pernambuco 51020-280, Brazil
  • CHN - Complexo Hospitalar de Niterói- Site Number : 0760008
    Niterói, Rio de Janeiro 24020-096, Brazil
  • Hospital Mae de Deus- Site Number : 0760003
    Porto Alegre, Rio Grande do Sul 90880-480, Brazil
  • Instituto Americas - Ensino, Pesquisa e Inovação - Rio de Janeiro - Avenida Jorge Curi- Site Number : 0760004
    Rio de Janeiro, 22775-001, Brazil
  • Clinica São Germano- Site Number : 0760001
    São Paulo, 04537-080, Brazil
  • Investigational Site Number : 1240001
    Toronto, Ontario M5G 2M9, Canada
  • Investigational Site Number : 1240004
    Greenfield Park, Quebec J4V 2H1, Canada
  • Investigational Site Number : 1240003
    Montreal, Quebec H1T 2M4, Canada
  • Investigational Site Number : 1520001
    Temuco, La Araucanía 4780000, Chile
  • Investigational Site Number : 1520003
    Santiago, Reg Metropolitana de Santiago 6900941, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 7580206, Chile
  • Investigational Site Number : 1520006
    Santiago, Reg Metropolitana de Santiago 7620001, Chile
  • Investigational Site Number : 1520004
    Santiago, Reg Metropolitana de Santiago 8380455, Chile
  • Investigational Site Number : 1520005
    Viña del Mar, Valparaiso 2540364, Chile
  • Investigational Site Number : 1560001
    Beijing, 100034, China
  • Investigational Site Number : 1560022
    Beijing, 100191, China
  • Investigational Site Number : 1560010
    Changsha, 410013, China
  • Investigational Site Number : 1560006
    Guangzhou, 510060, China
  • Investigational Site Number : 1560002
    Hangzhou, 310003, China
  • Investigational Site Number : 1560020
    Nanchang, 330006, China
  • Investigational Site Number : 1560019
    Nanning, 530021, China
  • Investigational Site Number : 1560011
    Qingdao, 266011, China
  • Investigational Site Number : 1560013
    Shenyang, 110004, China
  • Investigational Site Number : 1560007
    Tianjin, 300020, China
  • Investigational Site Number : 1560009
    Tianjin, 300052, China
  • Investigational Site Number : 1560018
    Tianjin, 300060, China
  • Investigational Site Number : 1560003
    Wuhan, 430022, China
  • Investigational Site Number : 1560008
    Wuhan, 430030, China
  • Investigational Site Number : 1560004
    Zhengzhou, 450008, China
  • Investigational Site Number : 2030005
    Brno, 625 00, Czechia
  • Investigational Site Number : 2030003
    Olomouc, 779 00, Czechia
  • Investigational Site Number : 2030006
    Ostrava, 708 52, Czechia
  • Investigational Site Number : 2030004
    Prague, 128 08, Czechia
  • Investigational Site Number : 2500002
    Nantes, 44093, France
  • Investigational Site Number : 2500005
    Paris, 75571, France
  • Investigational Site Number : 2500001
    Poitiers, 86021, France
  • Investigational Site Number : 2500009
    Saint-Priest-en-Jarez, 42270, France
  • Investigational Site Number : 2500003
    Toulouse, 31059, France
  • Investigational Site Number : 2500007
    Tours, 37032, France
  • Investigational Site Number : 2760005
    Dresden, 01307, Germany
  • Investigational Site Number : 2760003
    Heidelberg, 69120, Germany
  • Investigational Site Number : 2760006
    Lübeck, 23562, Germany
  • Investigational Site Number : 2760007
    Nuremberg, 90419, Germany
  • Investigational Site Number : 3000002
    Athens, 106 76, Greece
  • Investigational Site Number : 3000001
    Athens, 115 28, Greece
  • Investigational Site Number : 3000003
    Pátrai, 265 04, Greece
  • Investigational Site Number : 3000004
    Thessaloniki, 570 10, Greece
  • Investigational Site Number : 3480002
    Budapest, 1085, Hungary
  • Investigational Site Number : 3480004
    Budapest, 1097, Hungary
  • Investigational Site Number : 3480003
    Kaposvár, 7400, Hungary
  • Investigational Site Number : 3480008
    Pécs, 7623, Hungary
  • Investigational Site Number : 3480005
    Székesfehérvár, 8000, Hungary
  • Investigational Site Number : 3480006
    Szombathely, 9700, Hungary
  • Investigational Site Number : 3800004
    Torette, Ancona 60020, Italy
  • Investigational Site Number : 3800001
    Meldola, Reggio Emilia 47014, Italy
  • Investigational Site Number : 3800006
    Rome, Roma 00168, Italy
  • Investigational Site Number : 3800002
    Bologna, 40138, Italy
  • Investigational Site Number : 3800005
    Brescia, 25123, Italy
  • Investigational Site Number : 3800003
    Pavia, 27100, Italy
  • Investigational Site Number : 3920001
    Nagoya, Aichi-ken 467-8602, Japan
  • Investigational Site Number : 3920007
    Kamogawa, Chiba 296-8602, Japan
  • Investigational Site Number : 3920005
    Higashiibaraki, Ibaraki 311-3117, Japan
  • Investigational Site Number : 3920010
    Yahaba, Iwate 028-3695, Japan
  • Investigational Site Number : 3920012
    Kamakura, Kanagawa 247-8533, Japan
  • Investigational Site Number : 3920002
    Okayama, Okayama-ken 701-1192, Japan
  • Investigational Site Number : 3920003
    Kyoto, 603-8151, Japan
  • Investigational Site Number : 3920011
    Osaka, 530-8480, Japan
  • Investigational Site Number : 3920004
    Tokyo, 150-8935, Japan
  • Investigational Site Number : 3920009
    Yamagata, 990-9585, Japan

Showing the first 100 of 128 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ailawadhi S, Spicka I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Besisik SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minarik J, Goldschmidt H, Zhang R, Semiond D, Suzan F, Stefanova-Urena M, Koch V, Moreau P. Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study. J Clin Oncol. 2025 Aug;43(22):2527-2537. doi: 10.1200/JCO-25-00744. Epub 2025 Jun 3. PubMed 40459178 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Nov 2024, 28 months.

Results were first posted in Nov 2025, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 28 months is below that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2022
First posted
Jun 6, 2022
StartActual
Jun 23, 2022
Primary completionActual
Nov 6, 2024
CompletionEst.
Oct 22, 2027
Results first posted
Nov 14, 2025
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05405166
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 6, 2022
Start date
Jun 23, 2022
Primary completion
Nov 6, 2024
Completion
Oct 22, 2027 (estimated)
Results posted
Nov 14, 2025
Last update
Sep 2, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion